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Abstract 
 
Atrial fibrillation (AF) is associated with a high morbidity and mortality. Early 
identification of patients with AF may reduce morbidity and mortality. Current 
models predicting AF have limitations and focus on mainly clinical variables which 
are not always apparent in AF patients. Models focusing on pathophysiological 
mechanisms such as blood based biomarkers and ECG markers may be more accurate 
in identifying patients with AF. This study is based on the Birmingham and Black 
Country Atrial Fibrillation Registry (BBC-AF Registry) which recruited a cohort of 800 
patients with and without AF. Blood based biomarkers and ECG markers were 
compared between the two groups of patients. The blood based biomarker analysis 
using a novel proteomics chip technique demonstrated that BNP and a novel 
biomarker, fibroblast growth factor 23 (FGF-23) were increased in AF patients and 
were also independently predictive of AF. In the ECG analysis, QT interval was 
increased in AF patients and independently predicted AF. A combined model using 
blood based biomarkers, ECG markers and clinical variables demonstrated that a 
simple model consisting of simple clinical variables, QT interval, BNP and FGF-23 had 
a good ability to predict AF and performed better than contemporary AF prediction 
models in the current literature.  
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Chapter 1: Introduction 
For many centuries, physicians have been fascinated by the examination of patients’ 
pulse and their relation to overall human health. In writings dating back from over 
800 years ago, it is known that Maimonides, a prominent physician and astrologer 
from the Middle Ages, commented on a totally irregular pulse that was possibly atrial 
fibrillation (AF) (1).  
The same findings have been noted by other famous physicians such as William 
Stokes and Wenckebach (1). With the development of the electrocardiogram (ECG), 
the diagnosis of AF became more apparent and it became an increasingly recognised 
entity.  
Since then, there have been major advances in our understanding of both AF 
pathophysiology and also its potential treatments. In this first chapter, I will review 
the contemporary knowledge of AF and also cover the various biomarkers which are 
currently available for AF.  
 
Definition of AF 
The diagnosis of AF requires the documentation of a rhythm on ECG with the typical 
pattern of AF – absolute irregularity of RR intervals in an ECG with no discernible or 
distinct P wave activity. In order for the diagnosis to be confirmed, the arrhythmia 
must either be captured on a 12 lead ECG or last at least 30 seconds if it has been 
captured using ambulatory ECG recordings (2).  
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How common is AF and what are the consequences of a patient having AF? 
Worldwide, it is estimated that AF is prevalent in nearly 21 million men and 13 million 
women (3). In the middle aged population, studies suggest that 1 in 4 people will 
develop AF in their lifetime (4)(5) (6). It is estimated that the number of patients with 
AF is likely to increase 2-3 fold in the next 20-30 years (7). This increase is likely to be 
multifactorial but the major drivers are thought to be increasing age of the human 
population and also better detection methods for AF.   
There is considerable morbidity and mortality associated with AF. Firstly, it is 
estimated that patients with AF have a 1.5 to 2-fold increase in all-cause mortality with 
females having the highest risk (8). AF patients are also at an increased risk of 
developing ischemic strokes with studies showing that 20-30% patients who get 
admitted with an ischaemic stroke have had AF diagnosed either before, during or 
after the event (9). Patients with AF related strokes also have a poorer prognosis 
compared to patients who suffer a stroke without AF (10).  
Cardiac dysfunction in the form of heart failure is also common in AF patients; 
registry data suggests that the rate of heart failure is 33% in patients with paroxysmal 
AF, 44% in patients with persistent AF and 56% in patients with permanent AF (11).  
As well as co-existing in patients with heart failure, it is known that AF can be a 
causative mechanism for heart failure and also worsen heart failure in patients who 
are already known to have left ventricular systolic dysfunction(2).  
There is also considerable evidence to suggest that patients with AF have higher 
amount of white matter brain lesions, increased cognitive impairment (12) (13) (14) 
and also a decreased quality of life independent of other cardiovascular conditions 
(15) (16).  
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In addition to patient mortality and morbidity, there is also a significant healthcare 
cost associated with AF – estimated to approximately 1% of UK healthcare spending 
(17). The main costs are mainly thought to be due to AF related complications such as 
stroke and also treatment costs such as multiple hospitalisations for AF (2). It is 
therefore postulated that AF prevention and also timely AF treatment is likely to result 
in significant health economic savings.  
Types of AF.  
AF can be classified into various patterns depending on the presentation, duration 
and whether the AF episode spontaneously terminates. Based on these criteria, there 
are 5 different patterns of AF which have been recognised (2).  
a) First diagnosed AF – this refers to patients who have never had AF diagnosed 
previously. This is irrespective of the duration of the arrhythmia or presence 
and severity of AF related symptoms.  
b) Paroxysmal AF – this group refers to patients who have AF paroxysms which 
tend to self-terminate, usually within 48 hours. Some paroxysms however can 
persist for longer than 48 hours and can last upto 7 days.  
c) Persistent AF – refers to patients with AF who have lasting more than 7 days 
on rhythm control therapy. This includes patients who have been cardioverted 
either chemically or electrically after those 7 days.  
d) Long standing persistent AF – this category defines patients who have had AF 
for longer than 1 year on rhythm control therapy.  
e) Permanent AF – in this group of patients, both the physician and the patient 
have decided that AF should be accepted as the long term rhythm. There is 
usually no indication in this group of patients to pursue a rhythm control 
strategy.  
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Large observational studies have attempted to identify patterns in the natural history 
of AF and there is substantial evidence to suggest that AF is a progressive condition 
(18) (19). A substantial proportion of patients who have AF episodes are effectively 
asymptomatic (20). However, over a duration of time, these episodes can become 
longer and more frequent before sustained forms of AF then develop. However, this 
particular pattern of progression is not always consistent with a significant proportion 
of patients having paroxysmal AF for a long period of time without progression to 
persistent or permanent AF.  
Our understanding of the exact mechanisms underlying progression of AF remains 
limited but it is thought that AF progression is caused by a combination of the 
arrhythmia itself and also as a consequence of the progression of the underlying 
structural heart diseases.  
Pathophysiology of AF 
There are multiple risk factors which have been linked to an increased risk of 
developing AF such as increasing age, heart failure and coronary artery disease for 
example (See “Risk factors for AF section”). Even though these risk factors have been 
identified, the precise mechanisms underlying the development of AF remain poorly 
understood.  
The pathophysiology of AF is likely to be due to interactions between AF triggers and 
substrates. An AF “trigger” is a factor which causes rapid firing from a focus usually 
arising the pulmonary veins, initiating AF. A “substrate” on the other hand is the 
mechanical and anatomical structure of the atrium where AF can occur.  
Triggers of AF 
The pulmonary veins located in the left atria are thought to be most common sites for 
atrial firing which triggers AF. This critical concept was demonstrated by 
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Haissaguerre et al (21) and also led to the observation that catheter AF ablation using 
pulmonary vein isolation could be used to suppress recurrent AF.  
Atrial stretch due to various cardiac conditions such as valvular regurgitation for 
instance, can also increase the propensity of rapid firing from the pulmonary veins as 
a result of activation of stretch sensitive ion channels (22).  
In addition to the pulmonary vein triggers, there are also other non-pulmonary vein 
sites where rapid firing can occur to trigger AF (23). These include sites close to the 
pulmonary vein, the superior vena cava or sometimes the coronary sinus. There are 
also other supraventricular arrhythmias which have the ability to trigger AF such as 
atrioventricular nodal re-entrant tachycardia (AVNRT), atrioventricular reciprocating 
tachycardia and also atrial flutter.  
The exact interactions between these arrhythmias and AF is not entirely clear but atrial 
flutter and AF frequently co-exist in patients. There is evidence to suggest that in some 
instances, elimination of the atrial flutter can diminish or eliminate episodes of AF 
(24).  
Maintenance of AF 
Once AF is triggered, maintenance is usually via two major mechanisms which have 
been described at the tissue level: re-entry and rapid focal ectopic firing. Figure 1 (25) 
describes the main contemporary mechanisms which are thought to underlie AF 
maintenance. As shown by Figure 1 (A), AF can be due to a rapidly discharging 
ectopic focus or a single localised re-entry circuit (B). There is also evidence to suggest 
that AF may be caused directly by multiple functional re-entry circuits varying in time 
and space.  
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It is thought that these various mechanisms can be used as a basis to explain the 
various types of AF previously outlined. Paroxysmal AF for instance, is thought to be 
driven rapid focal activity or local re-entry around 1 or more pulmonary veins (21). 
  
Figure 1. Major AF maintaining mechanisms (Iwasaki et al (25)) 
 
 
Figure 2. Mechanisms underpinning AF maintenance in various AF types (Iwasaki 
et al (25). 
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As previously mentioned, AF is thought to be a progressive condition in many cases 
with evolution from paroxysmal to more persistent/permanent forms of the 
condition during the course of time (Figure 2). This process is thought to be due to 
atrial remodelling which can be caused by the arrhythmia itself (“AF begets more 
AF”) or progression of the underlying cardiac disease.  
As AF progresses and becomes more persistent, it is thought that functional and 
structural re-entry substrates become the predominant mechanism rather than local 
triggers and drivers which are the predominant mechanisms in paroxysmal AF (25). 
This difference in underlying mechanism is clinically relevant as it is well known that 
patients with paroxysmal AF respond well to catheter ablation using pulmonary vein 
isolation procedures whereas in persistent/long standing persistent cases, pulmonary 
vein isolation on its own is unlikely to restore sinus rhythm for long and more 
complex ablation procedures are required.  
Atrial remodelling 
As previously mentioned, atrial remodelling appears to be a central process involved 
the promotion of arrhythmias. The three main types of atrial remodelling are electrical 
remodelling, structural remodelling and autonomic remodelling (25), which are 
described below.  
Electrical remodelling refers to the modification of ion channel expression and 
function with the eventual result of further AF promotion. It can be caused by AF itself 
or other tachyarrhythmia. Calcium enters cardiac atrial cells with each action potential 
and therefore rapid heart rates, whether AF or other tachyarrhythmias, increase 
inward calcium loading. This increased calcium loading does pose a threat to cell 
viability and therefore autoprotective mechanisms are activated to reduce this threat.  
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The main processes that happen here include a combination of Ca2+ current 
inactivation, ICaL downregulation and also inward rectifier K+ current enhancement. 
The end result of these mechanisms is the reduction in action potential duration and 
therefore a reduction calcium loading. However, this reduction in action potential 
duration also reduces the refractory period and stabilise atrial re-entry mechanisms 
which makes the atrial myocardium more likely to develop further AF and also 
increases the ability to maintain AF. The altered calcium handling also increases the 
release of calcium during diastole and this promotes ectopic activity – a mechanism 
which is important both for triggering and maintaining AF.  
Structural remodelling of the atria also plays a key role in progression of AF. Clinical 
factors such as structural heart disease, diabetes and hypertension for example induce 
a process of structural remodelling of the atria. There is also evidence that AF itself 
tends to play a part in this process as it is known that even short episodes of AF are 
known to induce atrial damage. Atrial structural remodelling tends to occur via a 
combination of mechanisms including activation of fibroblasts, enhanced connective 
tissue deposition and fibrosis. One important consequence of structural remodelling 
and altered atrial structure is the fact that there is electrical dissociation between the 
muscle fibres with conduction heterogeneity. This tends to promote AF by favouring 
re-entry mechanisms.  
There is also evidence to suggest that various types of autonomic nervous system 
discharges play an important role in AF (26). Increased vagal tone is known to increase 
acetylcholine - dependent K+ current and this reduces action potential duration while 
increasing the propensity to AF by stabilising re-entrant mechanisms (27). Activation 
of the sympathetic nervous system on the other hand, via the B-adrenoreceptors, tends 
to cause an increase in diastolic calcium leak and promoting AF through delayed after-
depolarisations (DADs) causing increased firing from an ectopic focus.  
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Risk factors for AF 
Over the past 20-25 years, there have been multiple studies examining clinical risk 
factors which predispose patients to develop AF. The majority of these risk factors are 
involved in the process of atrial remodelling, which is felt to be a critical step in the 
development of AF. The current main risk factors for AF development and 
maintenance are as follows: 
a) Age – there is an increasing prevalence of AF with increasing age and this has 
been suggested by multiple large observational studies. One such study was 
the The AnTicoagulation and Risk Factors in AF (ATRIA) study was designed 
to estimate the prevalence of AF across the United States in the mid 1990s. 
Among a study population of 1.89 million people, they found a prevalence of 
17974 patients with AF. Among this group, they found clear age related 
differences in AF prevalence; patients who were younger that 55 years old had 
a 0.1% prevalence of AF compared to 9% in patients aged 80 years old or 
more(6). One possible explanation for this age related increase in AF prevalence 
is the increase in the amount of fibrosis with increasing age (28). This increase 
in fibrosis makes the atrial myocardium more susceptible to various re-entrant 
circuits and this facilitates AF. 
b) Hypertension: this is felt to be an important risk factor in developing AF in a 
significant proportion of patients. A study investigating the risk factors for AF 
in nearly 4000 male air crew recruits over a period of 44 years found that 
hypertension increased risk of AF by 1.42 times compared to normotensive 
male recruits (29). Epidemiological studies have found a 60-80% prevalence of 
hypertension among AF patients (30).  
c) Coronary artery disease: AF tends to be more associated with acute rather than 
chronic presentations of coronary artery disease. Patients presenting with acute 
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myocardial infarction have been found to have a 6-10 % prevalence of AF 
(31)(32). This phenomenon tends to be transient in the majority of cases and is 
thought to be due to mechanisms such as atrial ischaemia or stretching of the 
atrial walls secondary to heart failure as a result of the acute myocardial 
infarction.  
d) Valvular heart disease – the most common valvular lesion associated with AF 
appears to be mitral valve disease. Rheumatic heart disease which was a 
common cause of severe mitral valve disease is now uncommon in developing 
countries. However the association of rheumatic valve disease with AF remains 
strong and this has given us further insight into the relationship between valve 
disease in general and AF. A retrospective study examining the prevalence of 
AF in 1100 patients with rheumatic heart disease found that 70% of patients 
with a combination of mitral stenosis, mitral regurgitation and tricuspid 
regurgitation developed AF. In contrast 29% of patients with mitral stenosis  
and 1% of patients with isolated aortic valve disease developed AF (33). Mitral 
valve disease tends to be associated with atrial dilatation especially as the valve 
disease progresses and atrial dilatation itself contributes to atrial remodelling 
through previously outlined mechanisms.  
e) Heart failure – epidemiological studies, especially from the Framingham Heart 
Study cohort, have shown a close relationship between AF and heart failure 
(both HF with reduced and preserved ejection fraction). A recently published 
analysis from the Framingham Heart Study cohort with new onset AF or HF 
from 1980 to 2012 showed that AF occurred in more than half of heart failure 
patients. A third of patients with AF also developed heart failure. In terms of 
temporal relationships, this analysis found that AF can precede or follow heart 
failure (both with reduced or preserved ejection fraction) (34). Interestingly, 
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patients who develop both AF and heart failure have a worse prognosis than 
patients with each condition on its own(35).  
f) Diabetes mellitus – there is a high prevalence of diabetes in patients with AF 
and approximately 20% of AF patients are thought to have diabetes (30). 
Diabetes is considered to a significant risk factor for the development of AF as 
suggested by the Framingham Heart Study where the presence of diabetes was 
associated with a greater risk of development of AF in multivariate analysis 
(36). It is possible that diabetes leads to increased left ventricular mass and 
increased arterial stiffness; thereby perpetuating AF.  
g) Chronic kidney disease (CKD) – it is known that chronic kidney disease and 
AF share certain risk factors such as hypertension and diabetes and it is thought 
that CKD and AF have very close, intertwined relationships. There have been 
large studies studying the effect of kidney disease on AF risk. One such study 
from Japan followed up nearly 236000 patients over a follow up period of 5.9 
+/- 2.4 years to assess the effect of AF on CKD and vice versa. eGFR which is a 
surrogate measure of kidney function was found to be associated with 
subsequent AF. Hazard ratios for the development of AF were 1.32 (1.08-1.62) 
for patients with eGFR 30-59 ml/min per 1.73 m2 and 1.57 (0.89-2.77) for 
patients with eGFR <30 ml/min per 1.73 m2. Interestingly it was also noted 
that patients with AF at entry into the study had a greater risk of development 
of kidney disease and proteinuria over the follow up period. This dataset gives 
us an interesting insight into the relationship between these two conditions and 
suggests that they may share pathophysiological mechanisms in the form of 
abnormal signalling pathways(37).  
h) Thyroid disease –  hyperthyroidism (thyrotoxicosis) is a state of excessive 
thyroid hormone. The cardiovascular effects of hyperthyroidism have been 
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recognised for nearly 100 years. Epidemiological surveys investigating the 
prevalence of AF found that AF occurs in 9-22 % of patients with thyrotoxicosis 
and the reported prevalence of AF in the general population at the time was 
0.4%(38). It is hypothesised that the increased adrenergic tone may be 
responsible for AF development in thyrotoxic patients. It is also thought that 
there is increased automaticity and enhanced triggered activity of the 
pulmonary vein cardiac cells and these mechanisms form a focus of ectopic 
beats which can lead to AF.  
i) Obesity is associated with an increased incidence of AF. Every unit increase in 
body mass index (BMI) puts patients at a 3-8% higher risk of new onset AF 
irrespective of the presence of other cardiovascular risk factors (39) (40). The 
exact mechanisms behind obesity causing AF are not known. It is thought that 
left atrial dilatation may be a contributing factor but other possible mechanisms 
include the autonomic dysfunction and sleep apnoea.  
j) Obstructive sleep apnoea (OSA) has become increasingly associated with a 
variety of cardiovascular conditions such as hypertension. More recently, it has 
also been associated with an increased vulnerability to AF development (41) 
(42). It is hypothesised that airway obstruction can cause elevated intrathoracic 
pressures and this leads to an increased atrial stretch. OSA patients are also 
known to have intermittent hypoxaemia which can cause pulmonary 
vasoconstriction which in turns increases pulmonary artery pressures. OSA is 
also associated with increased autonomic dysfunction and diastolic 
dysfunction. This constellation of factors is believed to increase the risk of AF 
in patients with OSA. 
In addition to the above main risk factors for AF, there are also other chronic 
conditions which are associated with an increased risk of AF. In patients with 
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hypertrophic cardiomyopathy, it is well documented that up to 30% of patients may 
have AF. Whether AF affects prognosis in these patients is unclear – some studies 
suggest a worse prognosis whereas others do not show any increase in mortality 
(43)(44)(45). In patients with arrhythmogenic right ventricular 
dysplasia/cardiomyopathy (ARVC), atrial arrhythmias affect 14% of patients, the 
commonest atrial arrhythmia being AF (46). It is also recognised that patients with 
both long (47) and short QT intervals (48) are at an increased risk of AF.  
AF has also been reported in patients with congenital heart disease such as atrial septal 
defects with series reporting AF in upto a fifth of patients (49). Venous 
thromboembolism, including deep vein thrombosis and pulmonary embolus, are both 
associated with AF. In the International Cooperative Pulmonary Embolism Registry 
(ICOPER), which investigated the risk factors associated with death in pulmonary 
embolism in nearly 2500 patients, the prevalence of AF was 14% (50). The proposed 
mechanism contributing to AF is thought to be related to the increase in cardiac 
afterload and increased pulmonary vascular resistance due to pulmonary emboli 
causing strain in the right atrial tissues.  
However, there are patients who do develop AF without any obvious precipitating 
factors such as underlying structural heart disease – the so called “lone AF”. It is 
suspected that some of these “lone AF” patients may actually have underlying 
unknown risk factors that we are unaware of, including a genetic predisposition. To 
this end, more recent studies in the past few years have attempted to find potential 
risk factors in this group to explain their AF aetiology.  
Chronic alcohol consumption is associated with an increased risk of AF with some 
studies showing an increase in risk of developing AF by up to 34% in subjects who 
consumed more than three drinks per day (51). However, a large study of over 5000 
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patients found that alcohol intake was inversely associated with the risk of developing 
AF (the amount of alcohol consumed however in this study was low)(52). The link 
between chronic alcohol consumption and AF is therefore inconclusive as such.  
It is already well established that smoking increases the risk of cardiovascular disease. 
There is evidence from rat models to suggest that nicotine causes changes in atrial 
conduction and refractoriness and this may form a substrate for AF (53). Further 
studies investigating atrial fibrosis in patients, without known AF, undergoing 
coronary artery bypass surgery found that patients who smoked had increased atrial 
fibrosis – this was related to the development of AF post operatively.  
More recently, we have become increasingly aware of relationship between excessive 
endurance sports practice and higher prevalence of AF. Mont et al studied 107 
patients with lone AF and compared them with 107 age and sex matched controls. 
Patients who were diagnosed with AF performed longer durations of moderate and 
heavy intensity physical activity. These results suggested that accumulated lifetime 
physical activity along with height and left atrial size were independently associated 
with AF (54). However, there have also been contrasting results suggesting the 
opposite. A recent meta-analysis including 4 studies and comprising of 95526 patients 
did not find a significant association between regular physical activity and AF 
incidence(55). It has been postulated that increased sporting activity is associated with 
enlargement of cardiac chambers as an adaptive mechanism and this cardiac chamber 
enlargement is associated with structural and electrophysiological remodelling of the 
atria. Another possible mechanism could be that AF could be triggered by the 
increased vagal tone found in endurance athletes. The increased vagal tone results in 
bradycardia which in turn causes a shortening of the atrial refractory period and 
therefore favours AF. The role of anabolic steroids in AF development is not entirely 
clear but there are reports of sportsmen developing AF after use of such substances 
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(56) (57). The exact mechanism linking AF and anabolic steroids has not been 
elucidated so far.  
In young patients who develop AF with no obvious risk factors or structural heart 
disease, the possibility of genetic AF should be explored. Genetic loci such as ones on 
chromosome 10q22-24 have been identified for a form of monogenic AF since the mid 
1990s and since then other loci have been discovered (58). Genetic mutations in 
potassium channels (e.g. KCNQ1) and sodium channel genes (e.g SCN5A) have been 
identified as causes of AF. It is thought that these mutations cause changes in atrial 
electrophysiology by either altering action potential morphology or atrial conduction 
and this electrophysiological substrate becomes a driver for AF.  
More recently, Roselli et al (59) meta-analysed genome-wide association studies 
consisting of a total of more than half a million patients with nearly 70,000 AF patients. 
97 loci were identified as being significantly associated with AF. These identified loci 
have been found to be responsible for genes implicated in cardiac development and 
structure as well as electrophysiological pathways.  It is possible that future studies 
focusing on patient’s genetic makeup will be used to decide on targeted therapy for 
that patient including propensity to respond to anti-arrhythmic therapy. 
There has been increasing interest in the link between inflammation and AF. It is 
already known that markers of inflammation are increased after cardiac procedures 
such as cardiac bypass operations and the relationship between circulating markers 
of inflammation and development of AF in this group of patients has already been 
demonstrated in previous studies (60).  C-reactive protein (CRP) which is a marker of 
inflammation has been associated with the development of AF in healthy individuals 
(61) (62). Patients who already have known AF have higher levels of CRP than their 
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sinus rhythm counterparts – persistent AF patients had a higher level of CRP 
compared to the paroxysmal AF group (63).   
It is not entirely clear whether inflammation is a cause or consequence of AF. In a 
study investigating 52 patients undergoing cardioversion, high levels of high-
sensitivity CRP were associated with an increased recurrence of AF after 
cardioversion (64). This may suggest that inflammation is a cause of AF and increased 
inflammation leads to increasing difficulty in maintaining sinus rhythm. On the other 
hand, the same study found that high-sensitivity CRP levels decreased when sinus 
rhythm was restored and maintained – suggesting that AF is a cause of inflammation 
and that this inflammatory process regresses once sinus rhythm is maintained. 
Figure 3 summarises some of the major risk factors for AF and proposes an overview 
of the main mechanisms leading to AF. Schotten et al (7) proposed four positive 
feedback loops which acts as the main driving forces for atrial remodelling.  
The trigger loop is activated by excessive calcium loading during episodes of AF. This 
calcium overload also leads to an alteration in the ion currents in order to protect the 
cardiac myocytes against excessive calcium loading. However, this protective 
mechanism also causes a decrease in the refractory period and facilitates re-entrant 
circuits which then have the potential to lead to the development of more AF.  
The structural loop is driven mainly by chronic atrial stretch but also contributed by 
other processes such as fibrosis. The end result is again facilitation of the re-entrant 
circuits causing more AF.  
Chronic atrial stretch is also facilitated by the haemodynamic loop which is driven by 
AF with rapid ventricular rates causing forms of LV systolic impairment (tachy-
cardiomyopathy). It is generally thought that certain conditions such as structural 
heart disease, arrhythmias, ageing or inherited diseases trigger off one or more of  
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Figure 3. Overview of AF mechanisms – four different positive feedback loops. 
(Adapted from Schotten et al 2011(7)) 
 
 
the 4 loops. Due to the positive feedback mechanisms and interconnections between 
the 4 mechanisms, AF tends to stabilise with time (AF begets more AF). Therefore, the 
treatment of the underlying disease, if identified, must be of paramount importance 
to prevent AF from developing and also to prevent the progression of paroxysms of 
AF into more persistent forms.  
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Silent AF 
As previously mentioned, the prevalence of AF is estimated to be around 1-2% of the 
general population. However, there is significant evidence that this is a largely 
underestimated figure and that 40% of patients with AF may be asymptomatic, which 
is also known as “silent AF” (SAF) (65). Furthermore, patients who do have 
symptomatic AF appear to be aware of only 5-20% of their episodes (66).  
SAF is a term used to encompass the occurrence and detection of asymptomatic 
episodes of paroxysmal AF. There have been attempts to quantify such episodes of 
SAF and “AF burden” is a notion that has been proposed to quantify the amount of 
silent AF. AF burden (AFB) can be defined as the time spent in AF per unit of time 
(day/week/month)(66). 
In the current guidelines (2) on the stroke risk stratification in AF patients, AFB does 
not feature as a prognostic marker. These guidelines also do not distinguish stroke 
risk based on AF patterns (paroxysmal, persistent or permanent) and AF is treated as 
a dichotomous variable (absent/present). The current recommendations are based on 
data from controlled trials such as the Stroke Prevention in AF (SPAF) I-III which were 
performed between 1987 and 1997, and span to controlled trials that used almost 
identical inclusion criteria in this century, primarily including trials including the non-
vitamin K antagonists (NOACs) such as the RE-LY (67) , ROCKET-AF (68), 
ARISTOTLE (69) trials.  
Trials such as SPAF I-III compared stroke risk between paroxysmal and 
persistent/permanent AF in aspirin treated patients and found similar stroke rates 
between the two groups (70). However, a more recent study investigating stroke risk 
in 6563 aspirin treated AF patients found that the yearly ischaemic stroke risk 
increased in line with the AF progression. Yearly stroke risks were 2.1, 3.0 and 4.2% 
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for paroxysmal, persistent and permanent AF respectively. Multivariate analysis 
identified the pattern of AF as being a strong independent predictor of stroke risk (71). 
These findings call for larger studies in anticoagulated patients to confirm the 
different stroke risks associated with the different types of AF.  
With regards to symptoms, asymptomatic AF does not appear to be a benign 
condition (72). A recent meta-analysis however did not find any significant difference 
in all-cause, cardiovascular death or stroke/thromboembolic rates between patients 
with symptomatic and asymptomatic AF (73). Nonetheless, asymptomatic AF 
remains a serious condition with significant mortality and many patients may present 
only after serious complications such as thromboembolic stroke have occurred.  
To this end, one would anticipate that an earlier detection of AF could provide an 
important window of opportunity where clinicians could initiate therapies such as 
long term anticoagulation to reduce the risk of thromboembolic stroke and treatments 
to protect patients from progression of AF.  
There has been increasing importance placed on arrhythmia detection in silent AF 
populations and the current ESC guidelines have given a Class 1 indication for the 
opportunistic screening for AF in patients over the age of 65 years old by pulse 
examination or ECG rhythm strip analysis (2).  
A large systematic review addressing AF screening in populations by Lowres et al 
identified 30 individual studies with 122,571 patients and a mean age of 64 years old. 
It was found that screening using electrocardiography or pulse palpation had the 
ability to identify AF in upto 1.4% of the population aged 65 years old or over with 
previously unknown AF. A significant proportion of these patients were eligible for 
oral anticoagulation based on their thromboembolic risk profile. Therefore, simple 
 
 20 
measures such as pulse palpation or electrocardiography have the potential to reduce 
stroke and other AF associated complications in at risk older age groups (74).  
With the advent of much improved technologies, there have been many studies 
investigating the yield of AF using various forms of ECG monitoring, especially in 
stroke survivors.  
The EMBRACE study (30-day cardiac event monitor belt for recording AF after a 
Cerebral Ischemic Event) investigated the rates of AF detection using either a 30-day 
event triggered recorder or a conventional 24-hour monitor in 572 patients with 
cryptogenic stroke in the preceding 6 months. None of these patients had a prior 
history of AF. The 30 day event monitor group had a 5 fold increase in the rate of AF 
detection (16.1% v/s 3.2 %) compared to conventional 24 hour monitor (75). Indeed, 
current guidelines recommend that screening for AF should be carried out in all 
patients with TIA or ischaemic stroke using short term ECG recording and a 
continuous ECG monitoring strategy lasting at least 72 hours. It is clear from current 
evidence that the longer one looks for AF, the more AF is likely to be found with the 
highest yield of AF in stroke survivors being in those who have been implanted with 
loop recorders or who have had ECG monitors for several weeks (2). Newer 
technologies such as smart watches, blood pressure machines with AF detection 
algorithms and smartphones with ECG capability have become increasingly popular 
in the current market. Although these methods may play a useful role in AF detection 
in the future, there has been no formal evaluation of these techniques against 
established AF detection methods.  
Pacemakers and defibrillators with an atrial lead have also allowed us to monitor the 
long term atrial rhythm in these patients. This information can be used to identify 
patients with atrial high rate episodes (AHRE).  
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AHRE is identified in approximately 10-15% of patients with implanted pacemakers 
and defibrillators (76). The exact clinical implications of AHRE are still being clarified. 
Current evidence indicates that patients with AHRE have an increased risk of 
developing AF and also thromboembolic complications (2), but this risk appears to be 
somewhat lower compared to patients with overt AF. Studies using implantable loop 
recorders for long term monitoring have also indicated that not all AHRE represent 
AF (77).  
The ASSERT study (76) enrolled nearly 2600 patients over the age of 65 years old who 
did not have a clinical diagnosis of AF but had a dual chamber 
pacemaker/defibrillator implanted. At three month follow up, 10% of patients were 
found to have subclinical atrial tachy-arrhythmias (heart rate more than 190 beats per 
minute). Even after adjustment for conventional risk factors for stroke, these 
subclinical atrial tachy-arrhythmias were associated with an increased risk of stroke 
(hazard ratio 2.5, 95% CI 1.28 – 4.89 p=0.008). This study highlights the importance of 
detecting these AHRE episodes. 
 There are currently gaps in the evidence base as to whether patients with AHRE 
should be managed similarly to patients with overt AF especially with regards to 
thrombo-embolic stroke prophylaxis. In order to address these uncertainties, trials 
such as the Apixaban for the Reduction of Thrombo-Embolism in Patients with 
Device-Detected Sub-Clinical AF (ARTESiA) and Non vitamin K antagonist Oral 
anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET6) are 
currently ongoing.  
Current guidelines recommend that patients with ICDs and pacemakers should have 
their devices interrogated regularly for evidence of AHRE. If there is evidence of 
AHRE, AF should be confirmed with either further ambulatory ECG recording or 
 
 22 
reviewing any available device electrograms. Anticoagulation in these patients with 
confirmed AF then follows the standard management lines as per their stroke risk 
score (2).  
Given the various technologies available for silent AF detection, it is helpful to be 
aware of which population groups are likely to provide the highest “yield” of AF 
when screened. To this end, various parameters have been identified as indicating 
groups of patients at higher risk of silent AF. It appears that the higher risk groups 
include patients with hypertension, age, elevated BMI, diabetes mellitus, smoking, 
chronic kidney disease and previous cardiac disease are at higher risk of silent AF (78). 
Future screening programmes for AF may choose to focus their efforts on this higher 
risk group as this is likely to be where the highest yield of AF lies. 
So far, the various pathophysiological mechanisms of AF have been explored and 
mechanisms of how  various clinical risk factors contribute to the pathophysiology of 
AF have been described. Clinical risk factors which predict patients at high risk of 
silent AF have been identified.  
To date, there has been a relative lag in the use of additional markers predicting AF 
compared to areas such as coronary artery disease where this has become a routine 
part of management. There has been an increasing interest in the use of biomarkers 
such as troponin in the management of patients presenting with suspected coronary 
artery disease and in these situations, biomarker status does affect the patient’s 
management plan significantly.  
In other areas such as heart failure, biomarkers such as BNP have been used to identify 
patients at high risk of heart failure and having undiagnosed LV systolic impairment. 
The same rate of progress has not been made in the field of AF.  
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As previously outlined, in addition to the clinical risk factors identified, there are a 
proportion of patients with AF in which no clear risk factors at the time of diagnosis. 
There are various reasons why these conventional risk factors may not be apparent.  
Hypertension, a well-recognised risk factor for AF, may not be apparent at the clinic 
visit but may still be causing underlying structural changes to facilitate AF. A similar 
situation may be apparent for conditions such as atrial stretch. The most common 
method used for diagnosis of chronic atrial stretch is by echocardiography and this 
may not be readily available in all clinical settings. Therefore, these patients may have 
early signs of early structural remodelling in their atria but this is not picked up until 
the enlargement is significant and therefore the remodelling may be irreversible. 
Other pathophysiological mechanisms underlying AF genesis, such as fibrosis of the 
atria, are not easily detected non-invasively. Early detection of atrial fibrosis in a 
patient could indicate a patient at elevated risk of developing AF.  
There is therefore a significant need for improved and more sensitive methods to 
detect silent AF and also to detect early pathophysiological mechanisms which could 
indicate subclinical AF.  
One of the interesting areas which is being explored at present is the use of 
biomarkers to predict AF and this will be reviewed in the next section. 
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Biomarkers in prediction of AF 
What is a biomarker and what are the potential uses of biomarkers in AF? 
A biomarker has been defined by the Biomarkers Definitions Working Group as a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes or pharmacologic responses to a 
therapeutic intervention (79). This chapter will focus on the current blood based 
biomarkers that have been evaluated in predicting AF.  
Biomarkers, including blood based indices, are an appealing aspect of cardiovascular 
research because they have the ability to identify patients with a disease or subgroup 
form of a disease non-invasively and also allow us to glean into the 
pathophysiological mechanisms of the disease in more detail.  
In addition, biomarkers have the ability to provide important prognostic information 
about various cardiac conditions and this has already been demonstrated in fields 
such as heart failure for example, whereby elevated troponin levels are associated 
with worse outcomes.  
Given the high burden of undiagnosed silent AF previously described, it is therefore 
appealing to develop non-invasive biomarker panels which could be used to identify 
patients with early evidence of pathophysiological mechanisms that could lead to AF 
development (“high risk patients”).  
This could include biological processes such as early evidence of fibrosis or 
inflammation. This group of high risk patients could then be screened intensively 
using the methods described in previous sections to specifically target diagnosis of 
silent AF. Taking this concept even one step further back, identification of biomarkers 
that predate the development of AF may provide a window for early treatment 
strategies to be implemented so that clinical AF development may be prevented.  
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As previously mentioned, a significant proportion of patients with AF do not have 
any obvious risk factors and therefore screening using markers of pathophysiological 
mechanisms rather than clinical risk factors only, may be a more sensitive method for 
detecting at risk patients and also to detect silent AF.  
Biomarkers predicting incident AF should ideally be a reflection of the various 
mechanisms involved in the pathogenesis of AF. 
Broadly speaking, biomarkers predicting incident AF can be categorised into: 
a) Markers of atrial stress 
b) Markers of inflammation 
c) Markers of fibrosis 
d) Markers of kidney dysfunction 
 
Markers of atrial stress. 
Structural remodelling of the atria, usually with dilatation is thought to be a key 
underlying mechanism in the genesis and maintenance of AF. It is therefore plausible 
that biomarkers which reflect increased atrial pressures could be used as predictors 
for new onset AF.  
One of the most studied biomarkers in cardiovascular medicine are natriuretic 
peptides (NPs) with an abundance of evidence showing elevated levels in patients 
with LV systolic impairment. NPs, which include the B-type natriuretic peptide 
(BNP) and the stable N-terminal portion of the prohormone, pro-BNP (NT-proBNP), 
are synthesised by cardiac myocytes as a reaction to increased pressure in the cardiac 
chambers and increased myocardial stretch (80). Depending on the aetiology and 
severity of the cardiac disorder, NPs may either originate from the atria or ventricles.  
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In AF for instance, the main source of natriuretic peptides is thought to be the atria 
whereas the ventricles have been implicated to a greater extent in heart failure (81).  
There is an increasing body of evidence linking increases NPs levels to increased 
incidence of AF. The Cardiovascular Health study from the early to mid 1990s 
investigated the relationship between NT-proBNP and prevalent as well as incident 
AF. This was a large study of 5445 patients with a median follow up of 10 years. NT-
proBNP was the strongest predictor of incident AF even after adjustment for various 
covariables such as age, sex, mediation use, hypertension, diabetes, heart failure and 
echocardiographic parameters (82). The role of NT proBNP was further investigated 
in populations with more ethnic variations as part of the Multi-Ethnic Study of 
Atherosclerosis study. 5518 patients were followed up for nearly 8 years. NT-proBNP 
was significantly associated with incident AF and predicted AF strongly in Black 
patients, Hispanics and Asian/Chinese as well as the Caucasian populations (83). 
Schnabel et al (84) investigated the role BNP in the prediction of incident AF in the 
Framingham cohort consisting of 3120 patients. Median follow up was nearly 10 years 
and BNP was found to be a good predictor of incident AF and was found to be a useful 
addition to risk stratification in addition to clinical risk factors. Sinner et al (85) studied 
the role of BNP in a large cohort of patients consisting of 18556 patients from a 
combination of the Atherosclerosis Risk in Communities Study, Cardiovascular 
Health Study and Framingham Heart Study as part of the CHARGE-AF (Cohorts for 
Heart and Aging Research in Genomic Epidemiology AF) consortium. Patients were 
followed up for 5 years and BNP was found to substantially improve prediction of AF 
risk when added to a model consisting of clinical variables only.  
 In addition to the large community studies mentioned, the role of BNP and NT 
proBNP has also been studied in hospital inpatients in a range of clinical settings. In 
patients undergoing coronary artery bypass grafting, elevated levels of BNP and NT-
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proBNP preoperatively have been associated with an increased risk of new onset AF 
(86,87). However, other studies have shown conflicting results with Jogia et al 
demonstrating no significant association between elevated high preoperative NT-
proBNP and post-operative AF incidence (88).  
Suissa et al studied the role of BNP in stroke patients as part of the TARGET-AF study 
which was aimed at identifying clinical and blood based biomarkers which could be 
used to rule out delayed AF in stroke patients. 300 patients were enrolled and 17.3% 
of this group had newly diagnosed AF. An elevated BNP was found to be a useful 
marker in diagnosing incident AF.  Interestingly, their data also suggested that BNP 
had a high negative predictive value as well with a BNP level of </ 131 pg/ml being 
proposed as a cut off to rule out delayed AF in stroke survivors(89). 
Markers of inflammation. 
As previously outlined, inflammation is thought to play a key role in the 
pathophysiology of AF. Inflammation can trigger AF (and vice versa) which in turn 
can cause a further inflammatory response that further enhances atrial remodelling. 
Therefore, the AF triggered by the inflammation leads to even more AF. With regards 
to biomarkers, the acute phase reactant C-reactive protein (CRP) has been most 
widely studied.  
CRP is produced in the liver and there is some evidence to suggest that CRP may 
promote arrhythmia generation though a process of atrial remodelling and the 
associated consequences of this such as increasing atrial ectopy (90).  
There have been large observational data to suggest a significant link between 
elevated CRP and increased risk of incident AF. The Malmo Diet and Cancer Study 
(MDCS) cohort was analysed by Smith et al to assess potential risk factors for AF. 5187 
patients from this cohort were followed up for a mean period of 14 years. 284 patients 
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developed AF. CRP was found to be independently associated with AF even after 
adjustment for conventional risk factors (91). Schnabel et al studied 3120 patients from 
the Framingham cohort over a median follow up of 10 years. 209 patients developed 
AF in this cohort and CRP was one of the biomarkers independently associated with 
AF (84).  
However, there have also been conflicting results noted regarding the role of CRP in 
the pathogenesis of AF. Marott et al studied the association between elevated CRP 
and AF. This was a large study of 10,276 patients from the prospective Copenhagen 
City Heart Study as well as 36,600 patients from the cross-sectional Copenhagen 
General Population Study. Interestingly, in this study, the authors used a technique 
called Mendelian randomisation where genetic variants, which are associated with 
variable levels of plasma CRP, are tested to see if there is any relationship with plasma 
CRP and thus increased risk of AF. This study found that elevated plasma CRP levels 
were associated with an increased risk of AF but interestingly, genetically elevated 
CRP levels were not associated with AF. The conclusion therefore from this large 
study suggests that an elevated plasma CRP level per se may not increase AF risk (92).  
Markers of fibrosis 
Fibrosis is a key pathophysiological phenomenon in AF and there have been multiple 
studies examining various biomarkers which could be surrogate markers for fibrotic 
mechanisms and their ability to predict AF.  
One of the more widely studied biomarkers of fibrosis is galectin-3, which belongs to 
the family of β-galatoside-binding proteins. Galectin-3 expression has been detected 
in macrophages, eosinophils, neutrophils and also mast cells. It is also expressed at a 
tissue level and is most abundant in lungs, spleen, stomach, colon, adrenal glands, 
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uterus and ovaries. It is also expressed in kidneys, heart, pancreas and also liver but 
the levels in these tissues tend to be lower (93).   
It is already established that galectin-3 levels are increased in rats with decompensated 
heart failure. Furthermore, Sharma et al have demonstrated that galectin-3 infusion in 
the pericardial sac of normal rats led to development of cardiac remodelling with 
dysfunction (94). Galectin-3 appears to have a significant role in fibrosis which are 
important processes in cardiac remodelling and there have been various studies 
attempting to establish any possible links between galectin-3 and AF.  
Ho et al (95) analysed the role of galectin-3 in AF in a cohort of 3,306 patients from the 
Framingham Offspring cohort. 250 patients developed AF over a course of 10-year 
mean follow up. On univariate analyses, it was found that increased galectin-3 levels 
were associated with increased risk of developing AF. On multivariate analyses 
however, this association became non-significant when conventional risk factors 
known to predict AF were included. The results of this study suggest that increased 
galectin-3 levels may reflect underlying fibrosis which may lead to a variety of 
cardiovascular conditions and therefore the association is attenuated when clinical 
variables are added in the model.  
Transforming growth factor-beta1 (TGF-b1) is a member of the transforming growth 
factor beta superfamily and has been investigated as a marker of cardiac fibrosis both 
in human and animal models. The expression of TGF-b1 is highest in endothelial cells, 
vascular smooth muscle cells and also myofibroblasts (96). In mice models, increased 
expression of TGF-b1 was found to be associated with increased atrial fibrosis (97). 
Lin et al studied the effects of TGF-b1 in patients with AF secondary to essential 
hypertension. This was a small study consisting of 75 AF patients with 73 controls. 
TGF-b1 levels were found to be highest in the chronic AF patients compared to the 
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paroxysmal AF and sinus rhythm groups. There was an independent association 
between TGF-b1 levels and left atrial diameter, presence of AF, connective tissue 
growth factor and age (98). It is therefore plausible that TGF-b1 may reflect synthesis 
of connective tissue growth factor which causes enlargement and remodelling of the 
left atrium; subsequently leading to development of AF.  
Another member of the transforming growth factor beta superfamily is the growth 
differentiation factor 15 (GDF-15) which regulates cell proliferation and also 
apoptosis. Levels of GDF-15 are increased following myocardial stretch, in volume 
overload states and also inflammatory conditions.  Shao et al investigated levels of a 
group of biomarkers which included GDG-15 between 67 paroxysmal AF and 67 sinus 
rhythm patients. Patients with known paroxysmal AF had higher GDF-15 levels 
compared to sinus rhythm patients and GDG-15 was also independently associated 
with paroxysmal AF on multivariable analysis (99).  
Matrix metalloproteinase-9 (MMP-9) is an endopeptidase and member of the matrix 
metalloproteinase family. It has multiple biological actions and has been involved in 
vascular, proliferative and inflammatory conditions (100). Li et al investigated levels 
of MMP-9 in 75 AF patients compared to 40 healthy controls. The AF group was 
subdivided into paroxysmal, persistent and permanent AF subgroups with each 
group consisting of 25 patients. They found a significantly higher level of MMP-9 in 
AF patients compared to controls with levels increasing in line with the chronicity of 
the AF. This study, although small, indicates that MMP-9 may play a role in worsening 
interstitial myocardial fibrosis as well as structural remodelling and therefore could 
play a role in AF progression (101).  
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Markers of kidney dysfunction 
As previously mentioned, patients with chronic kidney disease have a higher 
prevalence of AF and there is a large overlap of associated conditions between chronic 
kidney disease and AF. There have been studies exploring biomarkers which could 
link both conditions. Reduction in kidney function is usually estimated using the 
glomerular filtration rate (GFR) which can be calculated using blood based 
biomarkers such as serum creatinine.  
Alonso et al explored the association of GFR as measured by cystatin C and creatinine 
in 10300 patients from the Atherosclerosis Risk in Communities (ARIC) Study over a 
10-year period. This study found that worsening kidney function as well as 
albuminuria were associated with incidence of AF independently of other recognised 
clinical risk factors (102). Watanabe et al prospectively observed 235818 Japanese 
patients and found a 1.3% incidence of AF over nearly 9 years’ follow-up. This study 
also found that worsening kidney function was associated with an increased risk of 
developing AF; in addition it also found that patients with AF were at higher risk of 
developing chronic kidney disease (37). Serum creatinine and measures of GFR are 
very commonly used in daily clinical practice already and based on the above studies, 
one may postulate that these could be useful as part of a multi-biomarker panel to 
predict the risk of AF.  
Fibroblast growth factor 23 (FGF-23) is a phosphate regulating hormone which is 
secreted by osteocytes and osteoblasts. FGF-23 mediates its actions via fibroblast 
growth factor receptors causing reduction in gastrointestinal phosphate absorption 
and stimulating phosphate excretion renally (103) (104). FGF-23 has been studied 
extensively in patients with chronic kidney disease with increasing levels indicating 
decreasing or worsening kidney function (105). In addition, FGF-23 levels are also 
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associated with increased risk of all-cause mortality and cardiovascular disease in 
patients with chronic kidney disease (106).  
The role of FGF-23 in the context of AF is unclear. Seiler et al (107) found that FGF-23 
levels were associated with AF and left ventricular function independently of renal 
function. Mathew et al (108) studied a large cohort of patients from the Multi-Ethnic 
Study of Atherosclerosis and Cardiovascular Health Study and found that incident 
AF was directly correlated with increasing FGF-23 levels. This association with AF 
was detected in patients without known cardiovascular disease; which makes a 
temporal relation between higher FGF23 expression and AF more likely. However, 
there have also been conflicting results from other large community based cohorts. 
Alonso et al studied 12349 patients as part of the Atherosclerosis Risk in Communities 
(ARIC) Study to help define the role of FGF23 further. Interestingly, over a mean 
follow up of 17 years, it was found that baseline FGF-23 levels were not associated 
with AF risk prediction independently of renal function (109).  
However, it remains unclear at this stage whether FGF-23 actually causes the 
disorders such as worsening kidney disease, cardiovascular disease or AF; or whether 
it is merely representing a compensatory response to these conditions.  
One of the proposed mechanisms linking FGF23 and AF could be explained by the 
fact that higher FGF23 levels are associated with LVH, vascular dysfunction as well 
as increased levels of inflammatory markers (107,110–112).  
It is therefore postulated that FGF23 can cause AF either as a direct action or by 
leading to the development of other cardiac conditions such as heart failure and 
culminating into AF. It is already known that patients with CKD have a higher 
incidence of AF and it is possible that higher FGF-23 levels could be contributing to 
the AF risk in CKD patients. 
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The various biomarkers investigated in the prediction of AF and the clinical 
surrogates that these biomarkers represent are summarised in Table 1.   
 
Table 1. Current known biomarkers associated with AF 
Biomarker category  
 
Markers of atrial stress 
 
NT-proBNP 
BNP 
             
          Markers of inflammation 
 
C-reactive protein 
 
Markers of fibrosis 
 
Galectin-3 
Transforming growth factor beta 1 
Growth differentiation factor 15 
Matrix metalloproteinase 9 
 
Markers of kidney dysfunction 
 
Glomerular filtration rate (creatinine 
/ cystatin C) 
Fibroblast growth factor 23 
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ECG markers predicting AF 
There has been increasing focus on potential ECG markers which can be used in daily 
clinical practice to predict incident AF in patients in sinus rhythm and also to detect 
paroxysmal AF.  
One of the main ECG markers of AF which has been studied is the P wave. The P wave 
on the ECG represents the atrial depolarisation wave and is generally accepted as the 
most reliable non-invasive marker of atrial conduction time (113).  
Abnormalities of P wave have been associated with abnormal pathophysiological 
mechanisms such as atrial fibrosis, dilatation and elevated filling pressures. These 
mechanisms reflect an abnormal atrial substrate which can increase the risk of incident 
AF as well as progression of AF. As previously described, many patients with AF will 
not have any obvious clinical risk factors, screening for patients at high risk of AF 
using methods reflecting pathophysiological processes can prove to be important in 
screening at risk patients.  
 
P wave duration 
P wave duration is one such P wave marker which has been studied in large cohorts. 
This is usually described as the interval between P wave onset and offset. Normal 
values of P wave duration are usually defined as <110ms. P wave duration reflects the 
transit time for electrical impulses generated in the sinus node to be conducted 
throughout the right and left atrium (114). Inter-atrial block is defined as the 
prolongation of the conduction time between the RA and LA due to impulse delay or 
blockage, resulting in prolonged P wave duration. Interatrial block in itself may be a 
risk factor for causation of atrial arrhythmias such as AF.   
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Previous studies have shown that patients in AF have longer sinus P wave duration 
compared to healthy controls (115).  
Magnani et al (116) used the Framingham Heart Study cohort to ascertain the 
relationship between P wave duration and longitudinal AF. 1550 patients over the age 
of 60 years old were studied over a follow up period of nearly 16 years. The upper 5% 
of P wave maximum duration had a hazard ratio of 2.51 for development of AF on 
multivariable analysis.  
Soliman et al (117) investigated P wave predictors of AF using the Atherosclerosis 
Risk in Communities (ARIC) Study which included 15429 patients with a follow up 
period of 6.97 +/- 1.46 years. On multivariable analysis which included common risk 
factors for development of AF, maximum P wave duration was noted to be the 
strongest predictor of incident AF (HR 5.23).  
However, there have also been smaller studies which suggest that AF patients have 
shorter P wave duration compared to healthy controls, indicating that increased atrial 
conduction could also be a substrate for AF (118). Investigators from the Copenhagen 
ECG Study (119) sought to investigate this further by analysing risk of incident AF in 
286933 patients over the course nearly 7 years. Nearly 10,000 patients developed AF. 
Interestingly, this study found that patients with very short (<89 ms), intermediate 
(112-119 ms), long (120-129 ms) and very long P wave duration (>130ms) had an 
increased incidence of AF compared to the reference group of patients with a P wave 
duration of 100-105 ms.  
Aside from this large study, most of the studies investigating the link between P wave 
indices and AF have been modest in size with sample sizes of 100 patients or less. The 
other issue with P wave indices in prediction of AF is the fact there are no standardised 
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values for “normal” P wave indices. There have been suggestions that P wave 
duration of 110 or 120 ms and above is abnormal and predictive of AF.  
However, there have been no prospective studies which identify a reference 
population which can then be used to investigate the link between P wave indices and 
AF as well as various risk factors for AF. The measurement techniques have also been 
varied across the various studies. Most of the studies have used hand held calipers 
and magnification glass to measure P wave duration with only a couple of studies 
using digitised ECG techniques. Digitised ECG techniques are probably more accurate 
and reproducible compared to manual measurements. Overall however, there are 
deficits in the standard technique and quality of measurements and therefore this is 
likely to be a major limiting step in the widespread application of P wave indices in 
AF and other cardiac conditions.  
 
P wave dispersion 
P wave dispersion has been suggested as another marker for predicting AF. It is 
closely related to P wave duration and it is defined as the difference between 
maximum P wave duration (P maximum) and minimum P wave duration (P 
minimum). It is known from previous studies that heterogeneous structural and 
electrophysiological properties of the atrial myocardium are thought to play a major 
role in mechanisms initiating atrial arrhythmias such re-entry. The inhomogeneous 
distribution of connections between fibres and bundles of fibres results in 
discontinuous and anisotropic sinus impulse propagation. This discontinuous 
impulse propagation is also contributed by fixed anatomical obstacles and site specific 
conduction delays. All these mechanisms are likely to play a role in the initiation of 
atrial arrhythmias such as AF. As the atrial impulses originate from various sites and 
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have non homogenous conduction, they are likely to have variable P wave durations. 
Therefore, patients with AF are more likely to show a higher variation in P wave 
duration and higher values of P wave dispersion.  
Dilaveris et al (120) investigated the role of P wave dispersion in 60 patients with 
idiopathic PAF and 40 aged matched healthy controls. They found that patients with 
PAF had higher P wave dispersion compared to healthy controls. P wave dispersion 
value of 40 msec separated patients with PAF from sinus rhythm with a sensitivity of 
83% and specificity of 85%.  
 
P wave area 
The use of P wave area as a marker of LA dilatation and stretch has been increasingly 
explored. Weinsaft et al (121) investigated the role of P wave area in 342 patients with 
coronary artery disease who underwent CMR, echo and ECG investigations. Left 
atrial area as determined by CMR was best correlated with P wave area in ECG lead 
V1 and interestingly LA area was less strongly correlated with P wave amplitude and 
duration. When these patients were followed up for a mean of 2.4 +/- 1.9 years, P 
wave area played an important role in stratifying longitudinal risk of atrial 
arrhythmias, similar to that provided by imaging by CMR.  Patients with the top 
quartile of P wave area had a nearly 3 fold higher risk of AF compared to the 
remainder of the population (HR 2.6 CI 1.1 – 5.9 p=0.02).  
The role of P wave area has also been investigated by Magnani et al (122). They 
conducted a cross-cohort meta-analysis of various P wave indices including P wave 
are in 3,110 FHS and 8,254 ARIC patients. P wave area was marginally but not 
significantly associated with AF risk at 10 years (HR 1.31 CI 0.95 – 1.80).  
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P wave amplitude 
The role and meaning of P wave amplitude in AF prediction is still not fully 
elucidated with only a few studies focusing directly on this. Jin-Kyu Park et al (123) 
investigated the role of P wave amplitude in predicting clinical recurrence of AF after 
AF radiofrequency catheter ablation (RFCA). 525 patients undergoing RFCA were 
included in the study. P wave amplitude was measured from the peak or nadir of the 
P wave to the isoelectric baseline (TP interval). The principal findings were that P 
wave amplitude in lead 1 was significantly lower in patients with recurrence 
compared to those who remained in sinus rhythm. At a follow up period of 21 +/- 10 
months, P wave amplitude in lead 1 was linearly associated with LA voltage and LA 
conduction velocity. P wave amplitudes of <0.1mV in lead 1 were independently 
associated with clinical recurrence of AF on multivariate analysis.  
It has been suggested that P wave amplitude indicates the direction of atrial 
depolarisation and atrial myocardial mass. P wave amplitude reflects the degree of 
atrial electroanatomical remodelling and inter-atrial conduction pattern. Therefore 
patients in AF who have inhomogenous atrial electrical propagation and decreased 
myocardial mass due to atrial scarring are likely to have smaller P Wave amplitudes 
as was found by Jin-Kyu et al (123). A smaller study by Gorenek et al (124) investigated 
the role of P wave amplitude  in the immediate recurrence of AF post internal 
cardioversion (two electrodes placed in right atrial appendage and coronary sinus 
respectively). The study cohort was small and included forty-five patients with 
chronic AF. 13 patients experienced immediate recurrence of AF post restoration of 
sinus rhythm. Patients in the immediate recurrence group had a shorter P wave 
amplitude in both lead 2 and V1 compared to patients who maintained sinus rhythm. 
Overall, P wave amplitude as a marker of AF has been understudied and there is a 
need for large studies to evaluate the potential predictive ability of this ECG marker.  
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PR interval 
The PR interval is another significant marker which has been explored as a potential 
predictor of incident AF. This is measured from the beginning of the P wave to the 
beginning of the QRS complex. The PR interval is thought to represent the electrical 
impulse propagation time from the tissue surrounding the sinus node through the 
atrioventricular node to the Purkinje fibres. Therefore, any conditions affecting the 
atrial or atrioventricular conduction such as fibrosis, ischaemia and autonomic tone 
can affect the PR interval. There have been multiple studies investigating the role of 
the PR interval in the prediction of AF.  
The Framingham Heart Study was one of the first studies investigating the role of PR 
interval in AF prediction (125). 7575 patients with a mean age of 47 years old were 
followed up from the late 1960s to 2007. During this period, 481 patients developed 
AF. The risk of AF was found to be higher in patients with a first degree heart block 
(PR interval >200ms) compared to patients without first degree heart block (HR 2.06 
95% CI 1.36-3.12 p<0.001). This association with AF was also evident during linear 
analysis of PR interval with longer PR intervals being associated with higher risk of 
AF (HR 1.11 for every 20ms increment in PR interval). Similar results were noted in 
the Atherosclerosis Risk in Communities (ARIC) study which studied AF predictors 
in different ethnic groups from a cohort of 15429 patients. Increasing PR interval when 
analysed as a linear variable was associated with risk of incident AF (HR 1.41 per 
25.4ms change 95% CI 1.20-1.65) (117).  
 
QT / QTc intervals 
QT interval is thought to reflect ventricular repolarisation. It is established that 
patients with both long (47) and short QT syndromes (48) are at increased risk of 
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developing AF. Furthermore, Nielsen et al (126) studied 280,000 patients from the 
Copenhagen region and found a J-shaped relationship between QTc and the risk of 
AF .  
Mandyam et al (127) assessed the use of QTfram ((calculated by formula QT + 0.154 x 
(1-RR)) as a predictor of incident AF in the Atherosclerosis Risk in Communities 
(ARIC) study and validated their model in the Cardiovascular Health Study (CHS) 
and Health, Aging and Body Composition (Health ABC). After correcting for 
covariates, a prolonged QT interval was found to be associated with an increased risk 
of incident AF. It is possible that increased QT interval may reflect an increased 
propensity to AF as a manifestation of irregularities in refractoriness in both atria and 
ventricles. Other studies suggest that a prolonged QT interval may reflect enhanced 
activity of the late sodium current which manifests as a prolonged QT on the ECG. 
This enhanced sodium activity increases the intracellular calcium which can lead to 
AF via triggered automaticity mechanisms.  
It is not entirely clear whether the relationship of prolonged QT interval with 
increased risk of AF is genetic, environmental or whether it merely reflects AF 
associated comorbidities.  
In this study, one of the aims will be to evaluate the independent predictive ability of 
QT interval in models consisting of clinical variables as well. This should help to shed 
more light on the role of QT interval in the prediction of AF.  
A summary of the main known ECG predictors is outlined in Table 2.  
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Table 2. Summary of the main known ECG predictors of AF.  
ECG parameter Role in AF 
 
P wave duration  
Surrogate marker for inter-atrial block (P wave duration 
>110ms).  
 
P wave dispersion 
Surrogate marker reflecting the inhomogenous impulse 
propagation in atria (longer P wave dispersion reflecting more 
inhomogenous conduction) 
 
P wave area 
Surrogate marker of LA dilatation and stretch (larger P wave 
area reflecting larger LA size).  
 
P wave amplitude 
Surrogate marker for the direction of atrial depolarisation and 
atrial myocardial mass. 
 
PR interval 
Surrogate marker of impulse propagation time from tissue 
surrounding sinus node through to AV node to the Purkinje 
fibres.  
 
QT / QTc interval 
Surrogate marker for irregularities in refractoriness of atria 
and ventricles / enhanced activity of late sodium current.  
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Current models used in AF prediction  
Given the major healthcare burden imposed by AF related complications, it has 
become increasingly important to investigate ways of identifying patients at risk of 
AF and patients who have undiagnosed AF. To this end there have been three main 
risk scoring systems derived from population-based cohort studies which will be 
reviewed in this section.  
a) The Framingham Heart Study  
A risk score predicting the risk of AF over a 10-year period was developed using 
patients from the Framingham Heart Study cohort (128).  4764 patients aged between 
45-95 years old, without known AF were followed up for the development of AF.  
Over this period, 10% of the patients developed AF. Multivariate models identified 
age, sex, body mass index, systolic BP, treatment for hypertension, PR interval, 
clinically significant murmur and heart failure as independent predictors of AF. The 
model had a fair predictive ability with a c-statistic of 0.78 (0.76 -0.80). Interestingly 
when echocardiographic parameters were included in the model, there was only 
minor improvement in the risk prediction. This model was only validated in 
Caucasian, middle-aged to elderly patients. 
b) The Atherosclerosis risk in Communities (ARIC) Study  
In this study, the authors aimed to develop an AF prediction score which would be 
applicable to the non-white population in contrast to the Framingham Heart Study 
score. The ARIC study (129) followed nearly 15000 patients over the course of 10 years 
to ascertain the incidence of AF. 515 patients developed AF during this period. The 
authors identified the following factors as part of the AF risk score: age, race, height, 
smoking status, systolic BP, hypertension medication use, precordial murmur, left 
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ventricular hypertrophy, left atrial enlargement, diabetes, coronary artery disease and 
heart failure. The model had a moderately good discriminatory ability (AUC 0.78).  
c) The Cohorts for Heart and Ageing Research in Genomic Epidemiology 
(CHARGE) AF consortium  
In this study (130), the authors pooled data from 3 community based cohorts for a 
derivation model. The pooled data included 18,556 patients from a combination of the 
ARIC, Cardiovascular Health Study and Framingham Heart study cohorts. The model 
was then validated in a pooled dataset consisting of 7672 patients from the Age, Gene 
and Environment – Reykjavik (AGES) and the Rotterdam Study cohorts. There were 
nearly 1200 cases of incident AF in the derivation cohort with 585 cases of incident AF 
in the validation cohort. The model derived included the following variables age, race, 
height, weight, systolic and diastolic BP, current smoking use of antihypertensive 
medication, diabetes and history of myocardial infarction and heart failure. This 
clinical model displayed a good discriminatory ability to predict AF at a 5-year period 
(AUC 0.765 (0.748 – 0.781)). When ECG parameters were added to the model, the 
discriminatory ability did not improve significantly. The model performed well when 
validated in the 2 pooled cohorts with C statistic 0.664 (0.632 – 0.697).  
d) Genomic AF scores 
There is increasing evidence that there may be a genetic basis to AF. In line with this, 
recent studies have focused on identifying associations between AF genetic risk scores 
and incident AF. Lubitz et al (131) examined the association between AF genetic risk 
and incident AF using data from five studies – the Malmo Diet and Caner study  
(MDCS), the Multi Ethnic Study of Atherosclerosis (MESA), the prevention of Renal 
and Vascular Endstage Disease (PREVBEND) study, the PROspective Study of 
Pravastatin in the Elderly at Risk (PROSPER) and the Vanderbilt University de-
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identified DNA biobank (BioVu). Data from 18,919 patients were analysed and over a 
5 year follow up period, 1032 patients developed incident AF. It was found that AF 
genetic risk scores were associated with incident AF after accounting for clinical risk 
factors. This study however emphasised that genetic risk scores only minimally 
improved prediction of AF beyond the predicting power of using models with 
established clinical risk factors. This is an area of evolving and exciting research with 
potential major implications for identifying AF in certain cohorts in the future.  
Roselli et al (59) also recently published a large meta-analysis of genome-wide 
association studies (GWAS) for AF. The cohort used for this analysis included more 
than 500,000 patients with over 65000 AF patients. 97 loci were identified as being 
significantly associated with AF and 67 of these loci were novel. The identified loci 
implicate genes which are potentially involved in various pathways causing and 
maintaining AF. It is envisaged that similar works will continue to improve our 
understanding of mechanisms underlying AF with therapeutic implications.   
A summary of the various variables of the contemporary models used for AF 
prediction is shown in Table 3. 
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Table 3. Summary of clinical models used for AF prediction 
Framingham Heart Study  
(AUC 0.78) 
ARIC study  
(AUC 0.78 )  
CHARGE-AF study  
(AUC 0.765)  
N= 4764 patients N = 14,546 patients  N = 18,556 patients in 
derivation cohort and 7672 
patients in validation 
cohort.  
Variables   
Age Age Age 
Sex Race Race 
BMI Height Height 
Systolic BP Smoking status Weight 
Treatment for hypertension Systolic BP Systolic BP 
PR interval Hypertension Diastolic BP 
Clinically significant 
cardiac murmur 
Precordial murmur Smoking 
Heart failure Left ventricular 
hypertrophy (ECG – 
Cornell Criteria) 
Antihypertensive treatment 
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 Left atrial enlargement  
(ECG – P wave duration > 
120 ms) 
Diabetes 
 Diabetes Heart failure 
 Coronary artery disease Myocardial infarction 
 Heart failure Left ventricular 
hypertrophy on ECG 
  PR interval. 
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As seen from the Table 3, the main advantages of these models are the large sample 
sizes with 5-10 year follow up. The studies with the larger sample sizes permit more 
variables to be included in the multivariate models. Overall, the models have a good 
ability to predict AF over a 5-10 year follow up.  
However, there are certain variables in the model which mean that these models 
become limited in the areas where they can be implemented. For example, 2 of the 
models include cardiac murmurs as a model variable. While evaluating murmurs may 
be applicable to appropriately trained staff such as physicians and some nurses, there 
will be many areas where patients at risk of AF present to and there may not be 
adequately trained staff to diagnose murmurs. Clinical examination skills such as the 
grade of the murmur for example are also exposed to subjective interpretations and 
this may mean that some patients are not adequately assessed.  
In routine clinical practice, AF patients without the above risk factors are also 
frequently encountered. It is possible therefore that screening for patients using a 
blood based biomarker may be a better marker for underlying pathophysiological 
abnormalities which could cause AF but have not manifested themselves yet in the 
form of LVH for example.  
Screening at a pathophysiological level using a blood test has multiple advantages 
such as more objective rather than subjective evidence, the more widespread 
availability of blood test compared to staff trained to listen to murmurs and so forth. 
The perceived disadvantage of a blood test based screening programme, at least in the 
short term, may be that some of the biomarkers being tested are not widely available 
in all the laboratories and also such an approach to screening may initially be more 
expensive than an approach relying on simple clinical parameters and an ECG.  
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In more recent literature there has been increasing focus on classifying AF based on 
their proposed mechanism in each individual patient. Fabritz et al (132) proposed that 
the incorporation of health modifiers which are known to cause AF should be used to 
classify AF based on their underlying mechanistic pathophysiological processes.  
This would allow more personalised and targeted management of AF patients. For 
example, AF caused in athletes by excessive physical activity may be targeted by a 
reduction of such activity whereas AF recurrence in patients with high BMI would be 
targeted differently by focusing on weight reduction. It is envisaged that such 
personalised therapy for AF is likely to improve outcomes of patients long term by 
employing the most appropriate AF treatment strategy for an individual patient.  
Summary of literature review and study aims 
AF can be multifactorial in aetiology but there is a large proportion of patients who 
do not have a clear cause of AF. Screening for AF in patients with clinical risk factors 
increases the yield of AF detection. Patients without clinical risk factors for AF may 
be missed by such approaches and therefore screening at even more basic 
pathophysiological levels may be warranted. Screening for AF using blood based 
biomarkers and ECG markers in addition to clinical risk factors is likely to yield the 
highest pickup rate for AF. In addition, biomarkers may help to distinguish different 
types of AF. 
My thesis therefore focuses on  
1) Investigating differences in blood based biomarker levels and ECG biomarkers 
between AF and non – AF patients  
2) Deriving various models to predict AF in an all comer cohort of patients 
presenting to a district general hospital in the UK.  
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This will be done by collecting and analysing data from the Birmingham and Black 
Country AF Registry (BBC-AF Registry) described in the next section (Chapter 2).  
The first results chapter (Chapter 3) describes the baseline characteristics of the AF 
patients in our cohort. The second results chapter (Chapter 4) focuses on the 
differences in blood based biomarkers between AF and non – AF patients. Models 
will be derived using biomarkers and clinical data to predict AF.  
The third results chapter (Chapter 5) will focus on the ECG parameter differences 
between AF and sinus rhythm patients and models will be derived combining ECG 
data along with clinical data to predict AF.  
The fourth results chapter (Chapter 6) will focus on combining results from the 
previous two chapters (4 and 5) to derive a combined model to predict AF using 
clinical parameters, blood based biomarkers and ECG markers.   
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Chapter 2  
Methodology 
Introduction  
As previously outlined in Chapter 1, the aim of this study is to investigate different 
non-invasive methods of identifying patients at risk of developing AF. 
In order to achieve these aims, differences in various types of biomarkers between AF 
and non-AF patients will be compared in a cross-sectional fashion. These biomarkers 
include blood-based biomarkers, ECG biomarkers and clinical parameters.  
In this chapter, the methods used in the project to achieve the above aims will be 
described. The main source of data to achieve these aims originated from the 
Birmingham and Black Country Registry Study (BBC-AF Study), which was the 
main project where patients were recruited over the course of 2 years. The data was 
collected by myself and a full time clinical research nurse. 
Design of BBC-AF study 
The BBC-AF study was a local registry that was set up in September 2014 to include 
patients from two groups; the first group included patients with known AF and the 
second group included patients who were not known to have AF but had pre-defined 
clinical characteristics putting them at an increased risk of developing AF (Table 4).  
Patients were mainly recruited from two main sites across the Sandwell and West 
Birmingham NHS Trust (City and Sandwell Hospitals).  The study was approved by 
the relevant authorities including the Research Ethics Committee and also the local 
NHS Trust Research and Development department. The study was conducted in 
compliance with Good Clinical Practice Guidelines and according to the declaration 
of Helsinki. The sponsor for the study is the University of Birmingham and the 
 
 51 
conduct and analysis was supported by European Commission (FP7: EUTRAF, and 
H2020: CATCH ME).  
Ethical approval was obtained to recruit up to 1600 patients from the above sources 
after they met the inclusion criteria (outlined in Table 4). Patient exclusion criteria are 
also listed in Table 4. The patients who are known to have AF were stratified into 
different sub-groups for different analyses (for example by classifying the AF by 
character rather than duration e.g. paroxysmal, persistent, long standing persistent 
and permanent AF).  
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Table 4: Inclusion and exclusion criteria 
Risk factors in non-AF patients  
Inclusion criteria 
One of the following 
Age 75 years old or more 
Prior stroke or TIA 
Or two of the following 
Age 65 years old or more 
Female 
Hypertension (includes patients on chronic treatment for hypertension, on 
antihypertensive treatment or resting BP of 145/90 mmHg) 
Diabetes mellitus (tablets or insulin) or impaired glucose tolerance 
Severe coronary artery disease (MI past or present, CABG or PCI) 
Stable heart failure (NYHA 2 or more or left ventricular ejection fraction of less 
than 50%) 
Left ventricular hypertrophy on echocardiography (12 mm or more) 
Peripheral artery disease 
And 
Able to provide signed informed consent 
Aged 18 years old or above 
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Exclusion criteria 
Age less than 18 years old 
Unable to consent 
Unable or unwilling for follow up 
Unwillingness to undergo investigations required by the study such as 
echocardiography and event recorders.   
Life expectancy at recruitment less than 1 year 
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Enrolment 
Initially when the recruitment into the study started in September 2014, the prevailing 
protocol only permitted patient recruitment from outpatient settings. Patients were 
mainly recruited from the cardiology outpatient clinics at the Sandwell and West 
Birmingham NHS Trusts. Patients were informed about the study and given the 
relevant patient information sheet.  
They were then invited for an appointment at the Ascot Clinic at City Hospital for 
enrolment at a later date. As can be envisaged by this outpatient recruitment system, 
there was a significant proportion of patients who could not make it to subsequent 
appointments and therefore the patient attrition rate was around 50%.  
To overcome this problem with recruitment, a revised protocol was implemented to 
expand our recruitment potential. An amendment was added to the original protocol 
to permit recruitment from inpatient wards, medical assessment units and the 
accident and emergency unit. This amended protocol was submitted to the Research 
and Ethics Committee and was approved in January 2015. Since January 2015, patient 
recruitment was expanded to both inpatient and outpatient setting.   
In the initial phases of the study from August 2014, I was the main patient recruiter 
for this study with some assistance from other research nurses.  In April 2015, we 
recruited a full time research nurse to work on the BBC-AF Research registry full time.  
In the initial phases of the study, it was anticipated that the target of 1600 patients 
would be achieved by the end of two years. However, there were some funding issues 
around the investigations required for the patients as part of the enrolment (especially 
the 7-day event recorders). The study was therefore temporarily on hold for around 2 
months where recruitment was minimal. As expected, this affected the number of 
patients that could be recruited within the time that I was working on the study.  
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Recruitment procedure 
The research team which included our research nurse and myself went onto the 
inpatient wards on a daily basis to identify potential patients for recruitment. Once 
suitable patients were identified, informed consent was taken prior to enrolling the 
patient into the study.  
All patients provided written informed consent in accordance with Good Clinical 
Practice (GCP) guidelines. Our study complied with the Declaration of Helsinki, was 
approved by the National Research Ethics Service Committee (BBC-AF Registry, West 
Midlands, UK, IRAS ID 97753) and sponsored by the University of Birmingham, UK.  
 Each patient then followed the recruitment procedure outlined below: 
A 20mls peripheral blood sample was taken by staff competent in phlebotomy 
(myself or a trained Research Fellow or Research Nurse). The blood was collected in 
two 10 ml EDTA bottles. A 12 lead electrocardiogram was recorded on the patient 
using standard limb and chest lead positions. The ECGs were recorded digitally using 
a Schiller MS2010 ECG machine which was purchased specifically for this project. The 
ECGs were recorded in an anonymous fashion using only the “BBC-AF ID” and 
patient initials. The next step after the ECGs and the blood tests involved filling in the 
quality of life questionnaires and cognitive assessment questionnaires.  
For the purposes of assessing cognitive ability, we used the Montreal Cognitive 
Assessment (MoCA) questionnaire.  Quality of life was assessed using the SF12 and 
EQ5D questionnaires. We assisted the patients with the MoCA portion of the 
questionnaire and the remaining two questionnaires were filled by the patient 
independently.  
During the course of the recruitment visit, clinical details were obtained from the 
patient and this was complemented by information in their clinical notes. Clinical 
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information included basic demographics, past medical history, social history, 
Karnofsky scores, NYHA scores and EHRA scores where applicable.  
To ensure that standard data was collected about each patient, a data collection set 
outlined in a uniform case report form was followed as part of the recruitment 
protocol. This case report form has also been transcribed electronically into an access 
database (see below in “Data Handling”) where the data is subsequently entered. 
Recent routine blood test results done for clinical reasons were also recorded as part 
of the data collection.   
As part of the study protocol, patient also required echocardiography and a 7-day 
event recorder if they were not known to have AF at the time of recruitment to rule 
out the presence of silent AF.  
The hospital clinical archive was reviewed for each patient recruited, and if the patient 
had an echocardiogram in the past 12 months, this was not repeated. If the patient had 
a 7-day event monitor in the past 12 months prior to recruitment, this was not repeated 
as part of the study.  The  patients’ clinical notes were appropriately documented to 
make it clear that the patient had been enrolled into the BBC-AF Registry. 
After the recruitment was done on the wards, all the samples were transferred to the 
Ascot Clinic, which was our main onsite research base for this project. The blood 
samples were centrifuged at 4000 revolutions per minute for 15 minute as per 
recommendations from our colleagues involved in sample analysis at the University 
of Birmingham. There were initial trial runs at 3000 revolutions per minute which 
appeared to be possibly unsatisfactory with regards to adequate plasma separation. 
The speed of centrifugation was therefore increased to 4000 revolutions per minute 
which provided satisfactory results. It was important to reach a balance between 
adequate separation of blood components and also to prevent haemolysis of blood 
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samples, which could happen if the samples were spun at excessively high 
revolutions.  
Once the samples are centrifuged, they were pipetted into appropriate containers for 
storage. 5 separate containers were used to distribute the storage of the samples. The 
plasma component was carefully pipetted to avoid any red cell contamination and 
was stored in two 1.8mls eppendorf containers. The remaining plasma that did not fit 
into the eppendorfs was stored in a sterile universal container. The next layer left after 
the removal of the plasma is known as the “buffy coat” layer, which contains the white 
blood cells and platelets and lies on top of the red cell layer. The “buffy coat” layer 
can subsequently be used for DNA extraction and analysis. This “buffy coat” layer 
was pipetted and split into two 1.8mls eppendorf containers. These samples were 
labelled with pre-printed stickers from the Biorepository department at the University 
of Birmingham. The stickers were anonymised and only contained the BBC-AF ID 
number and whether the sample was a “Plasma A, B or C” or “Red blood cell A or B”. 
The pipetted samples were stored in appropriate containers in a freezer at the Ascot 
Clinic site at -80C. The samples were transported in batches on dry ice to the 
Biorepository at the University of Birmingham where they were stored long term.  
An appointment was arranged by our administrative staff for the patient to be 
reviewed in 2 years for the follow up visit. Data collected during the initial visit was 
entered in a secure database by trained staff. This is outlined in more detail in the data 
handling section.  
Follow up 
As part of the long term aim of the BBC-AF Registry, patients will be followed up 
formally with an outpatient visit at 2 years’ time. At this visit, a 12 lead ECG, MOCA, 
EQ5D and SF12 questionnaires will be repeated. The patient’s medical history will 
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also be reviewed to assess disease progression at this visit and also to record any 
significant AF related complications.  
In the interim period in those two years, patient’s data was followed up via liaison 
with the patient’s GP and review of hospital notes if required. Patient’s GP could also 
be contacted at any point by the research team to check if there was any occurrence of 
major cardiovascular complications.  
Data handling 
During the recruitment, the data was initially recorded in a paper-based format, 
collecting the required variables outlined previously. The patient was assigned a 
unique BBC-AF ID number, which served as an identifier for the patient throughout 
the study.  
The containers that were used to store the samples were labelled with the BBC-AF ID 
number only rather than any patient identifiable information. Digital ECGs were 
labelled using this same BBC-AF ID number as the blood samples to maintain 
uniformity across the different datasets. A separate Excel datasheet was created which 
linked this unique patient identifier to the patient’s hospital number and personal 
details. This Excel datasheet was stored on the hospital secure server and was only 
accessible to members of the research team.  
Prior to starting this study in August 2014, a database with the appropriate forms 
using the Microsoft Access program was designed to record clinical data in an efficient 
and user-friendly format. This database also included an electronic case-report form 
(e-CRF) which followed the format of the data collection that was outlined in a paper 
based CRF which was approved by the local ethics committee. This Microsoft Access 
database was stored on a secure server in the hospital shared drive at the Sandwell 
and West Birmingham NHS Trust and permissions for access and editing were only 
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granted to selected members of the research team. Secure encrypted NHS email was 
used to communicate details about the patients in the BBC-AF between the research 
team members.  If data was transferred across computers, this was done using secure 
encrypted memory sticks provided by the hospital for safe transfer of confidential 
information.  
A separate Microsoft Access database was designed to record the levels of expression 
of different biomarkers in individual patients. This database was also stored on both 
secure shared server and also secure memory sticks as appropriate.  
Data analysis – blood sample analysis 
Our collaborating team at the University of Birmingham Cardiovascular Sciences 
department collected the samples stored in the University Biorepository for analysis. 
Dr Samantha Tull performed sample analysis at the University of Birmingham 
Cardiovascular Sciences laboratory using the Olink Proseek Multiplex Cardiovascular 
1 (CV1) 96x96 kit to simultaneously measure 92 biomarkers in plasma using real-time 
polymerase chain reaction.  
The results from this analysis were generated as Normalised Protein Expression 
(NPX) units, which were on a log2 scale. Higher values on this scale tend to represent 
higher sample protein levels. Similar studies using this Olink technique have focused 
on the discovery of new risk markers for ischaemic stroke with promising results 
(133).   
Olink Proseek Multiplex Cardiovascular 1 panel was the only biomarker panel used 
at the beginning of the project and biomarker data for the first 219 patients were 
obtained from Cardiovascular panel 1 only.  
Subsequently, in 2015, the Olink company ceased production of the Cardiovascular 
panel 1 and the 92 biomarkers were split into two separate biomarker panels (Panels 
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2 and 3). Based on previous pilot data where we analysed differences in biomarker 
levels between a smaller group of AF and sinus rhythm patients, we found a few 
relevant biomarker differences between the two groups. We therefore made a team 
decision to choose Cardiovascular Panel 2 as the preferred panel for biomarker 
analysis of the remainder of patients as this contained these relevant novel 
biomarkers.  
The Olink Proseek biomarker analysis is covered in more detail in section titled “Olink 
Proseek system” – proteomics.  
 
Data analysis- ECG analysis 
A Schiller MS2010 ECG machine was used to record digital ECGs in patients enrolled 
in the BBC-AF registry. This ECG machine allowed the recording of ECGs in both a 
PDF and XML format. The XML format of the ECG is the raw data format which can 
be processed using appropriate software to perform detailed analysis of underlying 
heart rhythms, especially the “complex” ECG analysis.  
To improve my knowledge of the analysis of complex ECG data, I visited the 
Cardiovascular Research team at the University of Maastricht in Netherlands in 
September 2014. During that period, I was trained in the use of ECG analysis software 
designed by the research team at the University of Maastricht. I learnt about the 
different steps in pre-processing the ECGs and the different methods of using the 
software to obtain accurate analysis results. I analysed a series of around 200 ECGs 
under supervision while in Maastricht to ensure that I was competent in this aspect 
before returning to Birmingham to continue the analysis.  
The software for the analysis was designed on the MATLAB programming software 
and I received training on how to use this software to use the relevant programs 
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depending on whether the ECGs analysed were sinus rhythm or AF. The ECG analysis 
technique and steps will be covered in further detail in the “ECG analysis” section.  
 
Statistical analysis of the data 
Data about biomarker levels was produced both in the linear and logarithmic 2 form. 
A pre-defined Excel macro produced by the Olink company converted the linear data 
into the logarithmic form and this normalised the distribution of the data which 
allowed the use of statistical techniques such as regression modelling.  
Categorical variables were analysed using the Chi-Squared tests. Continuous 
variables such as biomarker values for example, were analysed using independent 
samples t-test. Models using various logistic regression methods were created to 
assess which markers were associated with AF. ROC curves were created for the 
various models to obtain AUC and therefore decide on the predictive accuracy of the 
models.  
A p-value of less than 0.05 was considered to be statistically significant for the majority 
of variables except where multiple biomarkers were simultaneously tested. SPSS 
software Version 24 was used for statistical analysis. In analyses where multiple 
biomarkers were simultaneously tested for statistical significance, it is recognized that 
there is an increased risk of Type 1 errors occurring whereby there is a higher chance 
of a false positive. In order to address this potential problem, the Bonferonni 
correction will be used to derive an adjusted p-value and reduce the risk of Type 1 
errors and false discovery rate.  
More detailed methodology information for each specific analysis will be expanded 
on in the relevant chapters.  
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Summary 
In order to achieve the study aims of detecting patients with AF, data will be collected 
to build a moderate sized local registry of unselected patients with and without AF. 
Clinical data, ECG markers and blood based biomarkers will be collected and 
analysed with the aim of studying differences in these parameters between AF and 
non –AF patients.  
 
Chapter 2.1. Olink Proseek system – a detailed overview.  
In this chapter, Olink Proseek technology which has been used in the  BBC-AF 
Registry cohort to detect biomarker differences will be described in more detail.  
When the study initially started in August 2014, the initial biomarker analyses were 
performed using a panel of biomarkers known as the Olink Proseek Multiplex 
Cardiovascular Panel 1. This is a reagent kit which has the ability to measure up to 92 
pre-defined cardiovascular disease related human protein biomarkers 
simultaneously.  
As from 2015, the Cardiovascular Panel Multiplex 1 kit was ceased from production 
and therefore biomarker analysis for the remainder of our patients was done using 
Cardiovascular Panel Multiplex 2. Both panels use the same technology (but different 
chemistry) and analysis of biomarker levels as outlined below.  
 What is the technology behind Olink Proseek system? 
The Olink Proseek system is based on a unique technology known as proximity 
extension assay (PEA). This allows the measurement of 92 proteins across 96 samples 
simultaneously with the added advantage of only requiring one microliter of sample. 
The main steps of PEA technology are outlined below.  
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a) A pair of oligonucleotide labelled antibodies (Proseek probes) are allow to bind 
in pairs to the target protein present in the sample in a homogenous assay. No 
washing steps are required as part of this analysis.  
b) A proximity dependent DNA polymerisation process occurs when the two 
Proseek probes are in close proximity; allowing a new PCR target sequence to 
be formed.  
c) This PCR target sequence is then detected, amplified and quantified using 
standard real time PCR.  
One of the other advantages of this system is that each of the 96 oligonucleotide 
antibody pairs contains unique DNA sequences which allow hybridization only to 
each other. Cross reactive events are not detected with the Olink panels as only 
matched DNA pairs are amplified using real time PCR technology. A Fluidigm 
Biomark system containing both a Biomark HD Reader and IFC Controller HX for 96 
x 96 readout is required for detection and qualitification. Figures 4 and 5 illustrate this 
novel technology.  
How is the quality controlled in this process? 
The Olink system has inbuilt quality control systems which will are divided into 
internal and external controls. These have been designed with the purpose of 
monitoring the performance of the technical assay as well as the quality of the 
individual samples.  
The internal controls (2x Immunoassay controls, 1x Extension control, 1x Detection 
control) are added to each sample. The immunoassay control consists of two non-
human proteins and monitors all the three steps starting with the immunoreaction. 
The extension control consists of an antibody linked to two matched oligonucleotides 
for immediate proximity independent of antigen binding. This control monitors the 
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extension and readout steps and used for data normalisation across samples. There is 
also a detection control which consists of a synthetic double stranded template and 
this monitors the readout steps. Samples for which one or more of the internal control 
values deviate from a pre-determined range are flagged and may be removed from 
subsequent statistical analysis.  
 
Figure 4. Olink assay overview (adapted from Olink Proseek website (134)). 
 
 
Figure 5. Olink technology – advantage of preventing cross reactive events (adapted 
from Olink Proseek website(134)).  
 
 
Conventional immunoassays 
– cross reactivity as a result 
of antibodies binding non-
specifically  
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There is also an external control, also known as an inter-plate control, which is 
included on each plate and is used for a second normalisation step. This external 
control is made up of probes similar to the extension control but generated using 92 
matching oligonucleotide pairs. The external control improves inter-assay precision 
and allows for optimal data comparison from multiple runs.  
What data is produced at the end of the process? 
A pre-processing normalisation procedure is employed to quantify the protein 
expression. The technical variation within run and between runs is normalised. The 
values are then set relative to a correction factor determined by Olink.  
This generates a Normalised Protein eXpression (NPX) unit. This is on a log2 scale 
and higher values represent higher protein levels in the sample (background is 
usually zero). 1 NPX difference is equal to a two-fold increase in protein concentration 
(Figure 6).  
The data is also linearised by using the 2^NPX calculation. It is also possible to 
calculate the coefficient of variation using these linearised values. For the purposes of 
data analysis in my project, I will be using the NPX values both in the log2 and linear 
forms depending on the calculation required in line with the methods used by 
previous studies which have used this technology.  
Olink technology – only 
matched DNA pairs are 
detected and amplified. No 
cross-reactivity.  
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In terms of detection limits, this was calculated for the assays using recombinant 
protein antigen levels in pg/ml. Limit of detection (LOD) was defined as 3 standard 
deviations above background. One of the potential problems which can happen when 
using reagent antibodies is the so called “high dose hook effect” where there is a state 
of antigen excess relative to reagent antibodies. This results in falsely lower values 
which can lead to misinterpretation of results. The hook effect was therefore 
determined for each analyte (in pg/ml). For each sample, the measuring range was 
defined as the lower limit of quantification (LLOQ) and upper limit of quantification 
(ULOQ). These limits were calculated using the following criteria: relative error less 
than 30% and coefficient of variation of less than 30%. An example of analytical 
measurement data for one of the biomarkers (adrenomedullin) is shown in Figure 7.  
The mean intra-assay (within run) and inter-assay (between runs) variances were 9.1% 
and 11.7% respectively.  
Summary 
In summary, the plasma samples derived from the collected blood will be analysed 
using a novel proteomics chip technology which has the ability to detect and explore 
a large number of biomarkers simultaneously in nearly 100 patients per panel using 
only 1 microlitre of sample.  
The process is tightly quality controlled and has been used in multiple studies 
including the quantification of biomarkers in stroke medicine and neurological 
pathologies (133). Since the start of enrolment into the BBC-AF registry in August 
2014, there has been only one study which has used this custom-made proteomics chip 
technology to establish the association between novel biomarkers (NT-pro-BNP, FGF-
23 and GDF-15) and incident AF (135).   
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Figure 6. Comparison of NPX and linear values (adapted from Olink website (134).  
 
Figure 7: Calibration curve for adrenomedulllin and corresponding analytical 
measurement data (adapted from Olink Proseek website (134)).  
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Chapter 2.2 
ECG analysis 
In this chapter, the analysis of the ECGs that were collected for each patient will be 
described in more detail. 2 Schiller MS2010 ECG machines were purchased for 
collection of digital ECGs from patients enrolled in the BBC-AF registry. The ECGs 
were stored as both PDF and XML formats.  
The PDF format ECG was analysed by myself and used to record the “simple ECG 
parameters”. These simple ECG parameters (PR interval, QRS interval, QT interval 
and QTc interval) are usually automatically calculated by the ECG machine when 
recording the ECG. In order to ensure that the data automatically recorded was as 
accurate as possible, each ECG was also manually checked and the various intervals 
(such as PR and QRS interval) were visually inspected to minimise errors.  
Complex ECG analysis 
The XML file formats were used for “complex ECG analysis”. In this study, the 
specific complex ECG markers were analysed from ECGs recorded from patients who 
were currently in sinus rhythm at the time of ECG recording (irrespective of whether 
they have paroxysmal AF or not).  
Therefore, the complex markers analysed in this study are P wave duration, P wave 
dispersion, PQ time, P wave mean area and P wave amplitude. More detailed 
descriptions of these markers have been described in Chapter 1.  
As previously mentioned, P waves are a marker of interatrial conduction and usually 
have a smooth appearance on routine ECGs. Notched or more complex P wave shapes 
have been suggested as abnormal findings with some studies finding an association 
between notched P waves and cardiovascular events (136). P wave morphology 
changes are also associated with inter-atrial block which is known to predict 
 
 69 
supraventricular arrhythmias and left atrial electromechanical dysfunction. A study 
by Platonov et al (137) found that there were significant differences in orthogonal P 
wave morphology between patients with lone PAF and sinus rhythm patients, 
indicating possible inter-atrial conduction delay.  
One of the advantages of vectocardiograms (VCG) is that it provides spatial 
information which is not always apparent on a 12 lead ECG. However, VCGs are not 
usually recorded in clinical practice and therefore there has been increasing focus on 
deriving VCG information using a 12 lead ECG.  
Carlson et al (138) investigated if VCG indicators could be derived from a standard 12 
lead ECG (dVCG). 21 healthy subjects and 20 patients with AF were studied. This 
study found that the P wave shape was preserved after transformation from VCG to 
sVCG with consistent P wave morphology differences. A 12 lead ECG could therefore 
prove to be a useful alternate method of studying orthogonal P wave morphology.  
More recently, normal atria have been found to have highly complex P wave shapes 
on computer modelling. Potse et al (139) investigated P wave complexity in normal 
volunteers using high fidelity electrocardiographic techniques. 5 minute multichannel 
(256-channel) ECGs were recorded in 16 healthy volunteers and the noise and 
interference was reduced by averaging over 300 beats per ECG. This study 
interestingly found that, contrary to published medical literature, the true shape of 
the P wave is very irregular with measured P waves in this study having an average 
of 4.1 peaks. Patients with structurally normal atria have complexed-shaped P waves.  
In routine clinical practice, ECG printed traces usually show small sized P waves and 
are more suited for QRTS complexes analysis. Therefore, these systems are not 
adequately suited for complex P wave analysis.  
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However, it is known that patients even with normal atria may have complex P waves 
which may predispose them to supraventricular tachyarrhythmias. Therefore, 
methods to detect subtle abnormalities in P wave morphology are likely to be helpful 
to identify high risk patients earlier.  
The work done by Potse et al (139) is a step in the right direction with regards to 
identifying subtle P wave abnormalities but it does have some limitations. 
Multichannel ECGs are recorded over a 5-minute period with average signals taken 
from 300 beats per recording. While this may be a method to improve accuracy, it is 
unlikely to be used in widespread clinical settings mainly due to time limitations in 
recording ability with 256 channels and analysing the ECGs for the complex P wave 
abnormalities.  
Holmqvist et al (140) investigated an automated method of analysing the P wave 
duration and morphology in 131 healthy subjects using 12 lead ECG recording. P 
wave automated analysis had high reproducibility in terms of assessing P wave 
duration and P wave morphology. A sub analysis of the recording lengths varied from 
6 mins to 10 seconds and interestingly, the accuracy of the results was not affected by 
the length of the recording. This technique of automated P wave analysis was 
compared to manual P wave morphology measurements performed by two experts 
on two separate occasions to measure intra-rater reproducibility. Intra-rater 
reproducibility was 96%, inter-rater reproducibility was 94%. The automated method 
of classification agreed with the experts’ classification in 90% of cases. Therefore, 
shorter 10-second-long 12 lead ECGs which are routinely recorded in clinical practice 
can potentially be used for non-invasive studies of interatrial conduction.  
On the basis of the above principles and study results, a software has been developed 
by the Cardiovascular Research Institure Maaastricht at the Maastricht University in 
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order to analyse complex ECGs especially complex P wave morphology using raw 
data from a 12 lead ECG. The ECG analysis software has been designed on the 
MATLAB programming software. This program performs complex automated P 
wave analysis using XML files. During the course of the study, I visited the 
Cardiovascular Research Team at Maastrict University so that I could be trained in the 
use of this software. I analysed nearly 200 ECGs under supervision to ensure that I 
was competent in independently doing the remainder of the analysis when I came 
back to the UK.  
The principles of the complex ECG analysis using the Maastricht software are outlined 
below.  
1) The patient’s ECG in XML format is loaded into the Maastricht program.  
2) Artefact filtering is applied using high pass filtering (0.5 Hz) to exclude slow 
baseline drift due to thorax respiratory movement and 50Hz band stop filter to 
reduce power line interference.  
3) QRS complex identification. QRS complexes are identified automatically 
using energy signals and included according to similarity (cross-correlation 
coefficient p>0.9 applied to exclude artefacts and abnormal events such as 
premature ventricular ectopics). If the software did not detect a specific QRS 
complex, this could be manually adjusted by adding an extra QRS signal to the 
trace.  
4) P wave signal extraction. P wave information was then extracted relative to 
the QRS complex. To begin with, the default setting for extracting P wave 
information was set at 250 ms signal windows preceding each QRS complex. If 
the patient had an unusually long PQ time or P wave duration, the window 
could be manually adjusted to cover the P wave fully.  
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5) P wave signal averaging. The P waves with a cross-correlation coefficient of 
p>0.9 were grouped together and averaged. In a few cases where the P wave 
morphology was not easily detected by the software but could be clearly seen 
visually, the cross-correlation coefficient was reduced to p>0.8 in order to 
signal-average as many P waves as possible in the 10 second strip.  
6) A combined signal averaged P wave which was then analysed visually. The P 
wave onset and end as well as the start of the QRS complex were manually 
defined.  
7) Using the information derived from Step 6, the P wave duration and PQ times 
were derived.  
8) This process was repeated for all the ECGs of patients who were in sinus 
rhythm at the time of the ECG being recorded (this includes patients with and 
without AF).  
Using these steps, a database was created for “complex ECG parameters” which 
included P wave duration, P wave dispersion, PQ time, P wave mean area and P wave 
amplitude.  
Summary 
Abnormal P wave morphology may suggest abnormal intra-atrial conduction with 
subsequent predisposition to atrial tachy-arrhythmias such as AF. VCGs give extra 
spatial information but are not practical in routine clinical use. 256 lead ECGs can 
provide useful information about P wave complexity but are not practically useful 
either in day to day clinical use.  
Complex computer models have allowed us to derive spatial information from a 12 
lead ECG rather than having to rely on VCGs. A 12 lead ECG can be processed to give 
complex information about the morphology of the P wave. A software developed at 
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Maastricht University allows a near-automated method of deriving complex P wave 
information by inputing a raw XML 12 lead ECG file into the software.  
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Chapter 3 - Results 
Description of AF cohorts and comparison with current AF registries 
In this chapter, the baseline characteristics of patients recruited into the study will be 
described. The methods used for data collection for the BBC-AF study have already 
been described in Chapter 2.  
One of the unique features of the BBC-AF Registry study is the recruitment of patients 
from an unselected population of patients presenting to 2 district general hospitals 
(DGHs) in Birmingham.  
The study inclusion criteria were very broad with minimal exclusion criteria. The 
exclusion criteria were designed to be minimal so that collected data reflected a real 
life scenario of patients presenting to hospitals on a daily basis.  
The majority of patients were recruited at the “front door” in the Medical Assessment 
Units after being admitted to hospital for 24-48hrs. A significant proportion of patients 
were also recruited from the cardiology inpatient ward. A smaller proportion of 
patients (10%) were recruited from outpatient clinics and also sources such as cardiac 
rehabilitation.  
In this chapter, the baseline characteristics of the AF patients recruited in the study 
will be described and compared with data from larger AF registries. The baseline 
characteristics of sinus rhythm cohorts are described in later results chapters.  
Statistical analysis 
Continuous variables were expressed as mean +/- SD and categorical variables were 
expressed as a frequency and percentage. SPSS version 24 was used for data analysis.  
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Results 
Out of the total 720 patients, 338 patients had AF. The baseline characteristics of the 
AF cohort are illustrated in Table 5. The majority of patients were male (62%) and the 
mean (SD) age of was 71 (12) years old. Most of the patients were Caucasian with a 
minority of Asians and Afro-Carribean patients. The mean BMI was 30 indicating that 
most patients were overweight/obese.  
In the AF cohort of patients, the majority of patients had non-paroxysmal AF (49.6%) 
followed by paroxysmal AF (45.6%). 15 patients (10%) from the paroxysmal AF group 
were initially in the sinus rhythm group but reclassified into the paroxysmal AF group 
after AF was detected from the 7-day event recorders. A small proportion of patients 
had atrial flutter and atrial high rate episodes. 10% of the patients who were initially 
classified as sinus rhythm were reclassified into paroxysmal AF when their 7 day 
event recorder demonstrated evidence of atrial fibrillation. In terms of symptom 
burden, the majority of patients were symptomatic and in EHRA IIa/IIb categories 
(60%).  
In terms of comorbidities, just over half of the AF patients were hypertensive. 
Coronary artery disease was prevalent in just over a fifth of AF patients with a small 
proportion of these patients having a history of PCI. Clinically diagnosed heart failure 
was prevalent in 16% of patients and this group included patients with both impaired 
and preserved LV ejection fraction. Mean (SD) eGFR was 52 (31) suggesting that most 
patients with AF had a degree of renal impairment.  
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Table 5– baseline characteristics of AF patients in our cohort 
Variable Value % 
Male 210/338 62 
Age (SD) (years) 71 (+/- 12)  
Ethnicity   
Afro-Carribean 16/338 5 
Asian 25/338 7 
Caucasian 297/338 88 
BMI (SD) 30 (+/- 7)  
Systolic BP (SD) 126 (+/- 26)  
Diastolic BP (SD) 73 (+/- 15)  
   
Heart failure 53/338 16 
Stroke or TIA 35 /338 10 
Hypertension 186/338 55 
Coronary artery disease 72/338 21 
History of PCI 25/338  6 
Diabetes Mellitus 76/338 23 
Chronic obstructive 
pulmonary disease 
35/338 10 
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eGFR (SD) 52 (+/- 31)  
   
Type of AF   
Atrial flutter 14/338 4 
Atrial high rate episodes 2/338 0.6 
Paroxysmal AF 154/338 46 
Non-paroxysmal AF 168/338 50 
   
AF symptom burden 
(EHRA) 
  
EHRA I 55/338 16 
EHRA II (IIa and IIb) 203/338 60 
EHRA III 40/338 12 
EHRA IV 10/338 3 
 
Comparison of BBC-AF cohort with other contemporary AF registries.  
It is useful to gauge how the cohort of BBC-AF compares to other AF registries which 
have been published in the recent years. Two large registries are now described – the 
GARFIELD-AF registry and the PREFER in AF registry.  
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GARFIELD-AF 
GARFIELD-AF (141) is a worldwide, prospective observational study of adult patients 
with newly diagnosed AF with the aim of recruiting more than 50,000 patients overall. 
The two-year outcome data published in 2016 gave an interesting insight into baseline 
characteristics of patients with AF worldwide (across 35 countries).  
The two-year outcome data publication included 17,162 patients. There were certain 
similarities between the GARFIELD-AF cohort and the BBC-AF Registry cohort. Most 
of the AF patients were male and the mean age was similar (69.8 years in GARFIELD-
AF vs 71 years in BBC-AF). The vast majority of patients (65%) in the GARFIELD-AF 
study were Caucasian; this trend is similar to but somewhat less than the proportion 
of Caucasians in the BBC-AF Registry study. The body mass index of both cohorts was 
similar.  
In terms of significant comorbidities, there was higher percentage of heart failure 
patients in GARFIELD-AF compared to BBC-AF (21% vs 16%). The proportion of 
coronary artery disease, stroke and diabetes were similar across both cohorts. AF 
characteristics were somewhat different with the BBC-AF Registry cohort having a 
greater proportion of PAF patients compared to the GARFIELD-AF cohort.  
BBC-AF recruited patients who attended hospital either as outpatients or admitted as 
inpatients whereas GARFIELD-AF recruited from a broader range of sources 
including primary care and general practice. This difference in recruitment sources 
may explain some of the differences in baseline characteristics between the two 
cohorts. GARFIELD-AF also only recruited patients who were recently diagnosed 
with AF in the past 6 weeks. BBC-AF on the other hand, did not have such restrictions 
when recruiting patients. Patients recently diagnosed with AF, especially those 
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diagnosed in the past 6 weeks, are likely to display different baseline characteristics 
compared to a cohort of patients diagnosed with AF at any time.  
 
The Prevention of thromboembolic events- European Registry in Atrial Fibrillation 
(PREFER in AF) Registry 
The PREFER in AF Registry (142) was a prospective observational study designed to 
follow up AF patients long term in a European setting. It recruited 2743 patients in 
461 centres across 7 European Countries from January 2012 to January 2013. This 
study, in contrast to GARFIELD AF, had no explicit exclusion criteria and included all 
AF patients with an aim to recruit a cohort representative of “real life”. In that sense, 
PREFER in AF Registry is probably more similar to the BBC-AF Registry.  
In terms of baseline characteristics, both the BBC-AF and PREFER in AF registries had 
a majority of male patients. The mean age was the same (71 years old) across both 
registries. Stroke and coronary artery disease were more prevalent in the BBC-AF 
Registry compared to PREFER in AF. Patients in PREFER in AF however had a higher 
proportion of heart failure and hypertension.  
There were differences in the type of AF in both registries. BBC-AF had a higher 
proportion of patients with PAF compared to PREFER in AF (46% vs 30%). There was 
also no specific mention of atrial flutter in the PREFER in AF inclusion criteria so it is 
assumed that these patients were not included. BBC-AF on the hand recruited a 
proportion of patients with both atrial flutter and atrial high rate episodes.  
PREFER in AF recruited patients from a larger source including patients both in and 
out of hospital. BBC-AF did not recruit from outside the hospital setting including 
general practice for example. This difference in recruitment sources may to an extent 
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explain some of the differences in baseline characteristics. For example, a significant 
proportion of patients were recruited from cardiac wards in the BBC-AF study, which 
could explain the higher prevalence of coronary artery disease compared to PREFER 
IN AF which recruited more widely.  
Limitations 
During recruitment procedure, a significant proportion of the baseline data was 
collected from the clinical notes (e.g. Past Medical History etc). This process relies on 
the clinical notes being an accurate representation of the true clinical picture for that 
patient especially with regards to comorbidities.  
From my experience, most of this information in the clinical notes tends to originate 
from GP admission letters and there may be limitations to how accurate this 
information is. In terms of ensuring that the right information was collected from the 
source data, regular audits were carried out both by the research team and also by the 
hospital audit team. Two audits were carried out during the course of 2 years by the 
Trust Research and Development department where they checked the collected data 
against the source data. There were no major issues raised with regards to accuracy of 
the data.  
Conclusion 
In summary, BBC-AF Registry is the first registry of its kind to recruit an unselected 
cohort of AF patients presenting to 2 district general hospitals in Birmingham. There 
are minimal exclusion criteria which allows the registry to reflect a real life picture of 
AF patients presenting to hospital. The baseline characteristics of the BBC-AF Registry 
are to a large extent similar to large registries, especially those conducted in Europe; 
noted differences are likely reflective of the different recruitment strategies employed 
by these larger registries especially GARFIELD AF registry.   
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Chapter 4. Results. Investigating differences in biomarker levels 
between patients with AF and sinus rhythm using a novel proteomics 
chip. 
 Introduction 
AF, being the most common arrhythmia, and its associated sequelae have major 
implications for public health in terms of increased mortality and morbidity. The 
pathophysiological background of AF is not fully understood and multiple biological 
pathways have been explored. Most of the contemporary research into AF 
pathophysiology has focused on three main pathways: inflammation, oxidative stress 
and neurohumoral activity (143). 
In recent times, there has been a large focus on studies attempting to predict risk 
factors for AF and potentially identify patients at risk of developing AF long term. 
One of the main aims of identifying these “at risk” patients would be the potential to 
diagnose AF at an earlier stage and instigate the relevant treatments (such as stroke 
prevention using anticoagulants) to reduce AF related complications.  
Clinical risk factors such as age, race, height, weight, blood pressure, smoking, anti-
hypertensive medication use and history of myocardial infarction and heart failure 
(130) have been identified as the most important clinical risk factors for developing 
AF. 
In addition to clinical risk factors, there are also blood based biomarkers which have 
been identified as being potentially predictive of AF. These include N-terminal B-type 
natriuretic peptide (NT-pro-BNP)/ BNP, troponins, white cell count, low high density 
lipoprotein cholesterol, anaemia, renal failure, advanced glycation end-products and 
their receptors and C-reactive protein (135). However, for various reasons, none of 
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these biomarkers have been adopted in clinical practice for detection of patients at risk 
of AF. 
Proteomics has been used to investigate multiple biomarkers associated with 
cardiovascular diseases. One of the novel techniques involving proteomics is the 
Olink Proseek system. This technique is based on the proximity extension assay (PEA) 
technology and is able to measure upto 92 biomarkers related to common 
cardiovascular disorders. The Olink Proseek system along with the proximal 
extension assay technology has been described previously in Chapter 2.1.  
This technology has been evaluated in cardiovascular conditions such as stroke  (133) 
but there have been no specific studies investigating the use of this technology to 
detect biomarkers related to AF in unselected patients presenting to a district general 
hospital.  
So far, most analyses identifying biomarkers have been hypothesis-driven and 
involved measurement of a single or only several blood biomarkers (144). To 
determine the best biomarkers for predicting AF, we quantified 40 known 
cardiovascular biomarkers in a cohort of patients enrolled into the BBC-AF Registry 
as per previously defined inclusion criteria. 
The present study aims to evaluate: 
1) Differences in blood based biomarker levels between unselected patients 
with AF and sinus rhythm presenting to a district general hospital in 
Birmingham.  
 
The study hypothesis is that patients with AF will have higher levels of 
biomarkers related to oxidative stress and neurohumoral activity using a novel 
proteomics technique.   
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Methods 
The methods used in this study have been detailed in Chapter 2 and have been 
summarised here in brief.  
Study population 
Consecutive patients presenting to SWBH NHS Trust, Birmingham were recruited 
between September 2014 and August 2016. Eligible patients either had diagnosed AF 
(prior diagnosis or newly diagnosed) or at least two CHA2DS2-VASc stroke risk 
factors (“sinus rhythm patients but at high risk of AF group”).  
AF was diagnosed or confirmed by 12-lead ECG and those without diagnosed AF 
underwent 7-day ambulatory ECG monitoring to detect silent AF. Patients who 
initially classified as “sinus rhythm” were reclassified into the AF group if their 7-day 
event recorder demonstrated a new diagnosis of AF. 10% of patients who were in the 
sinus rhythm group were reclassified into the paroxysmal AF group after the result of 
the 7-day event recorder showed that these patients were having episodes of AF.  
Clinical information was obtained from a detailed interview, review of electronic 
patient records, and chart review. Transthoracic echocardiography was performed in 
all patients. This study complied with the Declaration of Helsinki, was approved by 
the National Research Ethics Service Committee (BBC-AF Registry, West Midlands, 
UK, IRAS ID 97753) and sponsored by the University of Birmingham, UK. All patients 
provided written informed consent. 
Biomarker quantification 
Samples from 720 patients were fractionated and stored at -80°C until analysis. Protein 
concentrations were quantified using a validated proximity extension assay which 
simultaneously measures 92 protein concentrations from 1 µl of plasma (Olink 
Proteomics, Uppsala, Sweden). Data from 82 patients (11%) were removed due to 
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assay failure or flagging during Quality Control. Protein expression was quantified 
and set relative to a correction factor to generate a Normalised Protein eXpression unit 
(NPX) - higher NPX values therefore represent higher protein levels with 1 NPX 
difference equalling a two-fold increase in protein concentration (fold change). Values 
below the detection limit of the assay were replaced by the lower limit of detection.  
 All data were analysed as log-2 transformed units (fold change). The data were 
divided chronologically with an approximate 60:40 split into the derivation cohort 
(n=384, analysed with Olink cardiovascular panel I) and validation cohort for model 
validation (n=254, analysed with Olink cardiovascular panel II). The 40 overlapping 
proteins between the two panels were included in the primary analysis.   
Statistical analysis 
Categorical variables were compared using Chi-squared tests. Continuous variables 
were compared using independent samples t-tests or Mann-Whitney U tests as 
applicable after testing for data normality with the Kolmogorov-Smirnov test. A two-
tailed p-value of <0.05 was considered to be statistically significant. 
For variable selection, all 40 biomarkers and seven clinical characteristics were 
considered: age, sex, hypertension, heart failure, history of stroke or transient 
ischemic attack, kidney function, and body mass index (BMI).  A complete list of all 
the 40 biomarkers used for the analysis is shown in the Appendix section of my thesis. 
As previously outlined in the Methodology section, there is an increased risk of Type 
1 errors when performing multiple analyses on the same dependent variable. In this 
case, this is likely to be an issue if multiple biomarkers are included in simultaneous 
statistical testing. In order to reduce this risk of Type 1 errors and false discovery rate, 
the Bonferonni correction will be applied to obtain an adjusted p-value to assess 
statistical significance of biomarkers. In the case of 40 biomarkers, the original p-value 
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of 0.05 is divided by 40 (number of biomarkers) to obtain a new adjusted p-value of 
0.00125.  
Forward stepwise selection with an entry criterion of p=0.05 was applied as an 
objective, data-driven technique to identify the minimum number of variables for the 
model to be practical and feasible for clinical implementation. A logistic regression 
model was fitted in the derivation cohort with rhythm (AF or no AF) as the outcome, 
and subsequently evaluated in the validation cohort.  
The area under the receiver-operator curve (AUC or c-statistic) and Brier score were 
calculated using SPSS v.24 (IBM Corporation, Armonk, NY).  
Results 
We recruited 720 patients for this biomarker cross sectional study. The basic 
demographics of the patients from both Cardiovascular Panel 1 and 2 are shown in 
Table 6. After exclusion of 82 patients due to various reasons, including incomplete 
biomarker data, data from 638 patients was used as part of the biomarker analysis.  
There were 384 patients analysed using Cardiovascular Panel 1 and 254 patients 
using Cardiovascular Panel 2.  The mean intra-assay (within run) and inter-assay 
(between runs) variances were 9.1% and 11.7% respectively. In the cohort of patients 
analysed using Cardiovascular Panel 1, there were 169 patients with AF and 215 
patients with sinus rhythm. There were 129 patients with AF and 125 sinus rhythm 
patients in Cardiovascular Panel 2.  
AF patients were older and had lower proportion of diabetes and coronary artery 
disease compared to patients in sinus rhythm. There was no significant difference in 
sex distribution, BMI, prior stroke, hypertension and heart failure between AF and 
sinus rhythm patients.  
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Patients in AF had significantly higher BNP levels compared to sinus rhythm patients 
in the derivation cohort (median [IQR]1.650 [0.522 – 3.917] versus 2.958 [1.458 – 4.589] 
p< 0.001). AF patients in the derivation cohort also had higher FGF-23 levels compared 
to sinus rhythm patients (median [IQR] 3.330 [2.784-3.984] vs 3.604 [3.067-4.946] 
p<0.001).  There was no significant difference in TRAIL-R2 levels between AF and 
sinus rhythm patients ( median [IQR] 3.52 [2.825 – 4.214]  vs 3.546 [2.794 – 4.298] 
p=0.727). 
Likewise, this pattern was observed in the validation cohort where both BNP (U= 
4994, p<0.001; Median [IQR] 1.689 [0.367-3.139] versus 3.191 [1.872-4.804]) and FGF-
23 levels (U= 5882, p<0.001; Median [IQR] 3.153 [2.624-3.961] versus 3.521 [3.061-
4.804]) were also significantly elevated as shown in Figure 8.  
Of the 47 clinical and biomarker variables, six were selected in the forward stepwise 
procedure. AF was more present in men than women; odds ratio 2.022 (95%CI=1.28-
3.56, p=0.008). For every one-year increase in age, the odds of prevalent AF were 1.060 
times higher compared to patients that do not have AF (95%CI=1.04-1.10, p=0.001). 
Similarly, BMI was associated with AF (OR=1.060 per BMI unit increase; 95%CI=1.02-
1.12, p=0.003). BNP and FGF-23 also displayed an increase in odds for patients with 
AF compared to those without AF; for every increase in a unit of fold change there 
was 1.293 (95%CI= 1.11-1.63, p=0.002) and 1.667 (95%CI= 1.36-2.34, p=0.001) fold 
increased risk of AF, respectively. In contrast, there was an approximate 76% decrease 
in odds for every increase in unit of fold change of TRAIL-R2 (OR= 0.242, 95%CI= 
0.14-0.32, p=0.001) for prevalent AF compared to no AF (Figure 9).  
This model had an AUC of 0.765 (95% CI 0.717-0.813) and a Brier Score 0.197 with 
comparable values in the validation cohort (AUC 0.684 [95% CI 0.62 – 0.75]) and Brier 
score 0.232.  
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As also seen in the ROC diagram in Figure 9, the addition of FGF-23 and BNP 
into the models increases the predictive ability of the model further compared 
to using only clinical variables (age, sex and BMI). There is an increase in the 
AUC in the model including biomarkers with a reduction in Brier score. 
Discussion.  
In this study, a novel proteomics technique was used to explore differences in new 
and known biomarkers between patients with and without AF. The results have 
highlighted some important points.  
Firstly, with regards to clinical risk factors, age and male gender are associated with 
AF as confirmed by previous studies (130). Secondly, with regards to biomarkers, BNP 
and FGF-23 were more likely to be associated with AF. Thirdly, a model based on the 
derivation cohort consisting of 6 variables (3 clinical and 3 blood based biomarkers) 
performed well in the prediction of AF. This model also had fair performance when 
used in a validation cohort.  
Increasing age is associated with increasing fibrosis of cardiac tissues and therefore 
increased risk of AF (28) . Male gender has also been associated with AF from previous 
studies and our results are consistent with existing literature.  
Fibroblast growth factor 23 (FGF23) (inflammatory pathway) 
FGF-23 is a protein which has been identified as having an important role in mineral 
metabolism with primary effects of phosphate reabsorption in the kidneys (108).  FGF-
23 acts on the kidney cells and promotes urinary phosphate excretion and also 
inhibiting production of 1,25 dihydroxyvitamin D, causing a reduction in dietary 
phosphate absorption.  
In patients with chronic kidney disease, increased FGF-23 levels are associated with 
long term all-cause mortality (145) as well as cardiovascular disease (146). More recent 
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studies have suggested an important role of FGF-23 in cardiovascular health in the 
general population (147). In human studies, higher circulating FGF23 levels have been 
associated with increased left ventricular mass (148) as well as increased incidence of 
heart failure, myocardial infarction and cardiovascular death (149). Left ventricular 
hypertrophy can lead to diastolic left ventricular impairment and subsequent rise in 
left sided chamber pressures. This rise in pressures has been associated with left atrial 
dilatation and fibrosis which has been shown to be an important precipitant for 
triggering AF. Studies have shown that FGF23 levels are increased and this increase 
in FGF 23 may explain the association between CKD and incident AF to some extent. 
The association of FGF 23 with AF is not entirely clear in patients who do not have 
significant renal dysfunction and multiple large studies have shown conflicting 
results.  
Our study results are in keeping with a large community based study which found 
that patients with higher FGF-23 levels had a higher risk of AF (108). Another recent 
study by Lind et al found that FGF23 was associated with incident AF in two large 
community based cohorts (135). However, Alonso et al (109) investigated the 
association between FGF-23 and AF in a large cohort from the Atherosclerosis Risk in 
Communities (ARIC) Study. This study which followed up a cohort of 12349 patients 
a mean follow up of 17 years did not find any significant association between baseline 
FGF-23 levels and AF risk.  
 To our knowledge, this biomarker analysis from the BBC-AF Registry study is the 
first to investigate the levels of FGF23 in an unselected cohort of hospital patients 
presenting with AF or sinus rhythm and demonstrating an increased level of FGF23 
in the cohort of AF patients compared to sinus rhythm patients. This study confirms 
the relevance of elevated FGF-23 levels for AF prediction in a comprehensive, data-
driven analysis. 
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B-Natriuretic peptide (neurohumoral pathway).  
BNP is a vasodilatory peptide secreted predominantly in the left ventricle in response 
to stress (135)(150). The precursor protein Pro-BNP is cleaved to form BNP and the 
amino acid terminal N-terminal pro BNP (NT-Pro BNP). The main actions of BNP are 
to promote systemic arterial dilation, natriuresis, diuresis and renin inhibition. With 
regards to cardiovascular diseases in general, studies have shown elevated BNP in 
patients with heart failure and also acute myocardial infarction.  
Silvet et al (150) demonstrated that patients with AF have higher BNP levels compared 
to patients without AF. BNP levels have also been found to be elevated in AF patients 
even in the absence of heart failure and other cardiac pathology. Our results, which 
show increased BNP levels in our AF cohort using a novel proteomics technique, are 
in keeping with these findings from previous studies and provide a reassuring marker 
with regards to the accuracy of this new technique.  
The mechanisms linking BNP and FGF-23 to AF remain under investigation with 
fewer studies exploring the role of FGF-23 compared to BNP. As BNP is a natriuretic 
peptide synthesised by cardiomyocytes in response to increased pressure and 
myocardial stretch, the association between BNP and AF suggests that pressure 
overload contributes to AF genesis in many patients.  
FGF-23 is a phosphate-regulating hormone primarily secreted by osteocytes and 
osteoblasts to modulate calcium homeostasis. As FGF-23 promotes myocardial 
remodelling and cardiac hypertrophy (110), it could lead to cardiomyocyte 
hypertrophy which increases ectopic activity and automaticity, leading to AF. FGF-23 
has also been associated with endothelial dysfunction, inflammation, and vascular 
calcification which can also enhance automaticity (112). It is possible that all of the 
mechanisms discussed contribute in some part to the development of AF in patients 
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with elevated FGF-23 (107,110,112). Our analysis suggests that heart failure (reflected 
by elevated BNP) and cardiac stiffness (reflected by elevated FGF-23) are two major 
drivers of AF, possibly pointing to two clinically relevant types of AF (132). Clearly, 
further research is warranted to understand the mechanisms linking elevated FGF-23 
and BNP to AF. 
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2 (TRAIL-R2)  
It is recognised that cellular apoptosis is an important component of atherosclerotic 
plaque formation as well as impacting the vulnerability of the plaque (151). Cellular 
apoptosis can be initiated via two different pathways – the intrinsic mitochondrial 
pathway and the extrinsic death receptor-associated pathway. A key component of 
the death receptor-associated pathway is the tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) which is present in macrophages, endothelial 
cells, vascular smooth muscle cells or released in a soluble form. TRAIL binds to 5 
distinct receptors, one of which is TRAIL-R2 which is recognised as the main 
apoptosis-inducing receptor. Activation of TRAIL-R2 has been shown to induce 
apoptosis in macrophages, vascular smooth muscle cells and endothelial cells and this 
is a possible mechanism causing vulnerable plaque formation. Gonçalves et al (151) 
studied the role of TRAIL R2 in predicting future cardiovascular events in 558 patients 
over a mean follow up period of 37 months. They found that higher TRAIL R2 levels 
were associated with human plaque cell apoptosis, plaque inflammatory activity and 
also symptomatic carotid artery disease. They also found that high TRAIL R2 levels 
independently predicted future cardiovascular event in patients with atherosclerotic 
disease.  
Mattison et al (152) investigated studied 4742 subjects from the Malmö Diet and 
Cancer Study over a 19 year follow up period to investigate if soluble death receptors 
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are markers of receptor-activated apoptosis and the role of death receptors in 
predicting the development of cardiovascular events and diabetes. They 
demonstrated that activation of apoptosis via the Fas ligand is associated with release 
of death receptors, one of the death receptors being TRAIL R2. Patients with high 
levels of TRAIL R2 at baseline were at higher risk of developing diabetes in later life. 
Higher TRAIL R2 levels were also associated with an increased risk of acute 
myocardial infarction.    
In our study, higher TRAIL R2 levels were associated with a decreased risk of having 
AF. This finding is somewhat surprising considering that higher TRAIL R2 levels 
increase the risk of diabetes and coronary artery disease, and both of these conditions 
are associated with an increased risk of developing AF. One possible explanation for 
this finding could be the cohort we that recruited for the study. In order to recruit AF 
patients, there was no requirement for any CHA2DS2-VASc risk factors to be present. 
However, in order to be recruited into the study as a sinus rhythm patient, the patient 
essentially had to have a CHA2DS2-VASc score of at least 2.  
A significant proportion of our patients recruited in the study were from the inpatient 
Cardiology wards. Patients who are admitted in a Cardiology ward usually will have 
an acute cardiac problem such as acute myocardial infarction and a predominant risk 
factor for development of acute myocardial infarction is diabetes. 
 Therefore, there is a significantly higher prevalence of diabetes and coronary artery 
disease in the sinus rhythm group compared to the AF group. On our logistic 
regression models, the TRAIL R2 may actually be an indicator of increased coronary 
artery disease and diabetes (who also have a higher prevalence of sinus rhythm in our 
cohort) based on published literature; rather than being a predictor of reduced risk of 
AF per se.  
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Clinical implications 
The results of our study have important clinical implications. Due to multiple factors 
outlined in Chapter 1, AF incidence is increasing and this trend is expected to 
continue. With this increase in AF, one may envisage that there will be an increase in 
AF related complications such as thrombo-embolic stroke. Patients diagnosed with 
AF are usually well managed with appropriate anticoagulation to reduce stroke risk.  
Of the major issues however, will be with regards to paroxysmal AF as these patients 
are more difficult to identify and unfortunately carry the same thrombo-embolic risk 
as patients with non-paroxysmal AF. These patients are therefore a large unidentified 
group of patients at high risk of stroke.  
The model derived from this study included all types of AF (paroxysmal and non-
paroxysmal AF). Although our model did not specifically differentiate for detection 
of paroxysmal AF, it is envisaged that it may be still be useful to detect patients with 
paroxysmal AF. Further larger scale studies are invited to validate our model in larger 
paroxysmal AF cohorts.   
From a clinical perspective, a point-of-care test for BNP and/or FGF-23 could allow 
screening for AF in many settings, including environments without immediate input 
from medically trained personnel. These “high risk” patients could then be screened 
intensively using various ambulatory ECG recording devices to identify “silent” AF 
with the aim of instigating appropriate treatments for AF before AF related 
complications develop.  
Identifying high risk patients could also be useful for improving efficiency of research 
into therapeutics by focusing limited resources on a selected group of patients rather 
than large unselected cohorts.  Further external validation is needed to determine if 
clinical characteristics and biomarker assessment of FGF-23 and BNP could be useful 
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for screening of AF. This would refine ongoing approaches using only age and BNP 
to select patients for screening (153). 
One of the strengths of the model derived in this study is that it includes simple 
clinical parameters (age, sex and BMI) which one encounters in daily clinical practice 
and also a series of blood based markers (BNP and FGF-23) which are available in a 
panel. In addition, the derivation model had better discriminative ability compared to 
current AF clinical risk scores such as the Framingham Study AF risk prediction score. 
To confirm the efficacy of the model further, it was validated in a smaller cohort of 
patients with similar clinical characteristics and here again the discriminative ability 
was better than current AF prediction scores.  
The model also provides a greater insight into the pathophysiological mechanisms 
underlying AF.  
BNP has already been validated in multiple studies as being increased in patients with 
AF. The role of FGF-23 in AF pathophysiology has not been fully investigated. FGF23 
levels have been associated with increased left ventricular mass as well as increased 
incidence of heart failure, myocardial infarction. Our multivariate model suggests that 
FGF 23 independently predicts AF even when combined with other AF clinical risk 
factors such as heart failure and myocardial infarction. It is therefore plausible that 
FGF23 may itself be indicative of an AF contributing pathway distinct from heart 
failure and myocardial infarction which are traditional and well known AF causing 
risk factors.  
Previous studies have shown that patients with CKD have an elevated FGF23 level 
and propose that this could partially explain the association between AF and CKD 
patients. However, our model proposes that FGF23 remains a predictor of AF 
independent of renal function when eGFR is used as a surrogate marker. This would 
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suggest that there may be distinct mechanisms causing AF which could also 
subsequently contribute to chronic kidney disease. The other alternative would be that 
there could be other separate mechanisms contributing to chronic kidney disease and 
also to AF pathogenesis and these mechanisms are expressed as an increased FGF23 
level as a surrogate marker.    
Limitations 
Our study does have important limitations which need to be taken into account. First 
of all, our cohort is an observational, cross-sectional study which was carried out in 2 
hospitals across one hospital trust in the United Kingdom and therefore the data 
pertains only to prevalent AF. Given the cross sectional nature of the study, there is 
currently no follow up data on the cohort of sinus rhythm patients and therefore the 
derived model cannot be validated prospectively.   
There are also potential observational biases for patient selection which may arise 
from the inclusion criteria. However, this cohort is a true representation of an 
unselected population of patients presently acutely to a large hospital and is very 
relevant for the outcome of interest.  
With regards to the new proteomics technique, the current model is derived on the 
NPX values (protein expression units) of the biomarkers (as outlined in methods). 
There are no current units for the biomarker levels which could be translated into a 
clinical laboratory. Therefore, in order to obtain a quantitative measure of the 
biomarker, one would have to perform an already established test such as ELISA to 
measure the protein level so that absolute values can be obtained for translation into 
clinical practice. The derivation of absolute values from the NPX values may prove to 
be a major step towards disseminating a more widespread use of the derived model 
in routine clinical practice.  
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Lastly, it is possible that there may be other clinical variables which contribute to AF 
which have not been accounted for in this model as we only used previously defined 
risk factors.  
Conclusion 
A novel proteomics technique has been used to derive a model, from a combination 
of 3 simple clinical risk factors and 3 blood based biomarkers, which has good 
discriminative ability to detect AF in an unselected population patients presenting to 
a district general hospital.  
This model has better discriminative ability as compared to contemporary models 
using mainly clinical risk factors. It has been demonstrated that it is possible to use a 
novel proteomics technique to explore the role of new and existing biomarkers in the 
prediction of AF. The results of this study invite for further larger studies to validate 
this model with regards to AF prediction in prospective cohorts of patients without 
known AF.   
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Table 6. Baseline demographics of patients in Cardiovascular Panel 1 and 2.  (* 
significant difference p<0.05) 
 Derivation (CV panel 1) Validation (CV panel 2) 
 
No AF  
n = 215 
AF 
n = 169 
No AF 
n = 129 
AF  
n = 125 
Age (years) ͣ 66.0 (57.0-
74.0) 
73.0 (63.0-
79.0)* 
67.0 (59.1-
74.0) 
75.0 (67.0-
81.5)* 
Male  130 (60.5) 117 (69.2) 83.0 (64.3) 68.0 (54.4) 
Ethnicity 
- Caucasian 
- Asian 
- Afro-Caribbean 
- Unknown 
 
133.0 (61.9) 
55.0 (25.6) 
25.0 (11.6) 
2.0 (0.9) 
 
142.0 (84.0)* 
14.0 (8.3) 
9.0 (5.3) 
4.0 (2.4) 
 
104.0 (80.6) 
13.0 (10.1) 
12.0 (9.3) 
- 
 
116.0 (92.8)* 
5.0 (4.0) 
4.0 (33.2) 
- 
BMI (kgm2) ͣ  28.1 (25.2-
32.7) 
29.6 (26.0-33.6) 29.1 (25.5-
33.4) 
28.9 (24.8-32.9) 
eGFR (mL/min/1.73 m²) ͣ 72.0 (57.0-
87.0) 
69.0 (57.5-84.0) 73.0 (58.3-
85.0) 
64.0 (44.5-
79.0)* 
Diabetes 89.0 (41.4) 37.0 (21.9)* 56.0 (43.4) 26.0 (20.8)* 
Stroke 24.0 (11.2) 21.0 (12.4) 13.0 (10.1) 10.0 (8.0) 
CAD 87.0 (40.5) 29.0 (17.2)* 78.0 (60.5) 29.0 (23.2)* 
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Hypertension 142.0 (66.0) 104.0 (61.5) 89.0 (69.0) 61.0 (48.8) 
Heart failure 31.0 (14.4) 28.0 (16.6) 8.0 (6.2) 12.0 (9.6) 
Ejection fraction (%) ͣ 60.0 (53.1-
67.3) 
57.7 (45.0-
65.0)* 
57.0 (45.5-
62.5) 
55.0 (41.3-61.0) 
  
Figure 8. Differences in levels of BNP and FGF-23 between AF and SR patients in 
the derivation and validation cohorts.  
  
Figure 9. Logistic regression model for predictors of AF.  
 
 98 
 
Chapter 5 Results 
Differences in simple and complex ECG markers between AF and 
sinus rhythm.  
Introduction  
As mentioned previously in Chapter 1, there have been multiple ECG parameters 
which have been explored as possible predictors of AF. This includes simple ECG 
markers such as PR interval, QT and QTc intervals as well as more complex ECG 
markers such as P wave duration, dispersion, area and amplitude.  
There have been conflicting results regarding the ability of these simple and complex 
ECG parameters to predict incident AF. So far, the AF predictive ability of these ECG 
parameters have been mainly evaluated in large community cohorts and not in 
unselected cohorts of patients presenting to district general hospital.  
Aims  
The aims of this study were to establish:  
1. if there was a difference in simple and complex ECG markers between 
patients who are in sinus rhythm and patients who have paroxysmal AF.  
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2. the ability of ECG markers to independently predict AF either alone or when 
combined with clinical variables in a cohort of unselected patients presenting 
to a district general hospital.  
 
Hypothesis 
For the simple ECG markers, the study hypothesis is that patients with PAF will have 
longer PR and QTc intervals compared to sinus rhythm patients. For the complex ECG 
markers, the hypothesis is that that PR duration will be longer in patients with PAF 
compared to sinus rhythm patients.   
Methods 
The methods used for collecting data from the BBC-AF Registry study have already 
been outlined in Chapter 2. Baseline clinical characteristics of both patient groups 
were obtained from clinical notes.  
Patients were classified in the sinus rhythm group if they did not have a diagnosis of 
AF at baseline and also if no AF was recorded on their event recorder. Patients in the 
paroxysmal AF group were only included in this analysis if the 12 lead ECG at the 
time of recruitment showed sinus rhythm but they were either known to have AF or 
if their event recorder had shown evidence of paroxysmal AF.  
Simple ECG parameters were obtained from electronic measurements from Schiller 
ECG machine readout with research staff visually inspecting and confirming the 
measurements. The methods outlining complex ECG analysis have been previously 
outlined in Chapter 2.   
Categorical variables were compared using Chi-squared tests. Continuous variables 
were compared using independent samples t-tests or Mann-Whitney U tests as 
 
 100 
applicable after testing for data normality with the Kolmogorov-Smirnov test. A two-
tailed p-value of <0.05 was considered to be statistically significant.  
ECG variables demonstrating independent prediction of AF on univariate analysis 
were then combined with clinical variables (age, sex, diabetes, coronary artery disease, 
heart failure, history of stroke or TIA, kidney function and body mass index [BMI]) to 
derive a combined model using logistic regression method.  
QT and QTc intervals are inter-related with the QTc being derived from QT interval 
via equations such as the Bazzett correction method for example. Therefore, only the 
QT interval will be included in the models for analysis in order to reduce the risk of 
collinearity affecting the results. QT interval was chosen instead of QTc based on the 
superior ability of QT interval to predict AF in the current published literature.   
Results 
153 patients with paroxysmal AF (with sinus rhythm ECG at baseline) and 341 sinus 
rhythm patients were included in this analysis. The baseline demographics of both 
groups are outlined in Table 7. 
Patients in the AF group were older compared to the sinus rhythm group and also 
tended to have worse renal function as reflected by a significantly lower eGFR. 
Patients in sinus rhythm had a significantly higher proportion of hypertension, 
diabetes and coronary artery disease compared to AF patients.  
In terms of ECG markers, there was no significant difference between complex ECG 
markers between the two groups. When comparing simple ECG markers, I found that 
patients in the AF group had a significantly longer QT interval compared to sinus 
rhythm patients (406 ms vs 396 ms p=0.016). A subgroup analysis by gender showed 
that there was no significant difference in either simple or complex ECG markers 
between the AF and sinus rhythm groups in male patients. In females, QT interval 
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was prolonged in the AF group compared to sinus rhythm and there was a trend 
which almost reached statistical significance (408 ms vs 396ms p= 0.06). There was no 
significant difference in PR interval between the two groups.  
Logistic regression model 
A logistic regression model comprising of simple ECG markers only showed that QT 
interval was an independent predictor of AF (p=0.028) as shown in Table 8. PR 
interval was not a predictor of AF in this model.  
The logistic regression model repeated using complex ECG markers only showed 
that P wave duration was independently associated with AF (p=0.007) (Table 9).  
A model combining both simple and complex ECG markers was then created and 
showed QT interval was an independent predictor of AF whereas P wave duration 
was not (Table 10).  
QT interval was then included in the final model. In a model combining QT interval 
with clinical predictors of AF, QT interval was independently predictive of AF 
(p=0.007). Hypertension (p=0.003), coronary artery disease (p=0.001) and diabetes 
(0.001) were independent predictors of sinus rhythm. Increased BMI (p=0.025) and 
increasing age (p=0.025) were independent predictors of AF (Table 11).  
Discussion 
The results of this study have shown that AF patients have a significantly prolonged 
QT interval compared to the sinus rhythm patients. QT interval is an independent 
predictor of AF in our cohort.  
As previously established, QT interval is thought to reflect ventricular repolarisation. 
It is established that patients with both long and short QT syndromes are at increased 
risk of developing AF.  
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Furthermore, Nielsen et al (126) studied 280,000 patients from the Copenhagen region 
and found a J-shaped relationship between QTc and the risk of AF . Mandyam et al 
(127)  assessed the use of QTfram (calculated by formula QT + 0.154 x (1-RR)  as a 
predictor of incident AF in the Atherosclerosis Risk in Communities (ARIC) study and 
validated their model in the Cardiovascular Health Study (CHS) and Health, Aging 
and Body Composition (Health ABC). After correcting for covariates, a prolonged QT 
interval was found to be associated with an increased risk of incident AF.   
The results of our study are consistent with the current literature and demonstrate 
that a simple ECG marker such as QT interval is a useful predictor of AF.  
It is possible that increased QT interval may reflect an increased propensity to AF as 
a manifestation of irregularities in refractoriness in both atria and ventricles. Other 
studies suggest that a prolonged QT interval may reflect enhanced activity of the late 
sodium current which manifests as a prolonged QT on the ECG. This enhanced 
sodium activity increases the intracellular calcium which can lead to AF via triggered 
automaticity mechanisms.  
It is not entirely clear whether the relationship of prolonged QT interval with 
increased risk of AF is genetic, environmental or whether it merely reflects AF 
associated comorbidities.  
In our study, a prolonged QT interval remained independently predictive of AF when 
combined with clinical biomarkers. This finding is also consistent with current 
literature. This is an interesting finding and suggests that a prolonged QT interval 
predicts AF via a separate mechanism distinct from the clinical variables.  
As outlined in Chapter 1 Figure 3 about the mechanisms of AF, it is proposed that 
there are 4 interacting loops representing various mechanisms 
triggering/maintaining AF. The clinical variables would tend to primarily represent 
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the structural and haemodynamic loops and the QT interval is likely to be a surrogate 
marker the electrical/trigger loops.  
Therefore, a simple ECG marker such as QT interval can be used to build a more 
comprehensive model of AF prediction representing the various mechanisms of AF 
generation and maintenance.  
Interestingly, PR interval was not significantly different between the AF and SR 
groups and a prolonged PR interval did not independently predict AF in the derived 
model. 
As previously mentioned, a prolonged PR interval is thought to represent delayed 
electrical impulse from the tissues surrounding the sinus node to the Purkinje fibres. 
Previous studies including the Framingham Heart Study and Atherosclerosis Risk in 
Communities (ARIC) study have found a higher risk of AF in patients with a 
prolonged PR interval. Other studies however, such as the Copenhagen ECG study 
found an increased risk of AF with both long and short PR intervals and a large 
Finnish study with a cohort of over 10,000 patients did not detect any association 
between prolonged PR interval and increased risk of AF.  
Our results could be due to differences in population cohorts compared to the above 
studies. The Framingham Heart Study cohort for instance, included a younger sample 
of patients with the mean age of 46 years old. This is contrast to the BBC-AF Registry 
cohort where the mean age ranged from 66-70 years old. It is already established that 
PR interval can reflect increased fibrosis in the atria which prolongs atrial and 
atrioventricular conduction. Fibrosis is a process that becomes more common with 
increasing age.  
Therefore, it is possible that because the BBC-AF Registry cohort consists of older 
patients, age related fibrosis may become more prevalent in both the PAF and SR 
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groups and therefore the difference detected by PR interval is likely to be minimal. 
The independent predictive value of increased PR interval is also likely to be blunted 
in these cases as increasing age leading to fibrosis is likely to play the more major role 
in prediction of AF compared to the ECG surrogate marker; therefore, increased PR 
interval does not remain independently predictive of AF when included in models 
which include age.  
As suggested by the Copenhagen ECG Study, both long and short PR interval were 
associated with increased AF risk in women but this association was only present for 
prolonged PR interval in males. This study had a much larger cohort of more than 
11,000 patients compared to our sample and this made it possible to investigate non-
linear relationships between PR interval and AF and highlighted the U shaped 
relationship. Given that our sample is smaller, it would not be possible to adequately 
investigate such relationships and therefore overall it may appear that PR interval as 
a whole does not independently predict AF.  
Complex ECG markers such as P wave duration were not significantly different 
between the two groups. It is possible that the population demographics in our cohort 
is significantly different from the cohorts previously studied and therefore the 
difference is in P wave duration does not become apparent.  
Many of the studies studying P wave duration have used paper caliper and 
magnification glass measurements instead of digital measurements. Paper 
measurements are associated with a larger intraobserver / interobserver errors 
compared to digital measurements. Therefore, it is anticipated that the digital 
measurements used in this study would be more accurate. Overall, there is no 
standard technique for measuring P wave duration in the literature which will be a 
major limiting factor in the widespread application of this technique in AF.  
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Overall, the results of this study suggest that a simple ECG marker (QT interval) is an 
independent predictor of AF when added to a multivariate model including simple 
clinical characteristics. This finding suggests that there is possibly a separate 
mechanism for AF generation and maintenance which is reflected by a prolonged QT 
interval as a possible surrogate marker. A model comprising of clinical markers 
(reflecting the structural and haemodynamic loops) as well as simple ECG markers 
(reflecting the electrical and trigger loops) is likely have an increased accuracy in the 
ability to predict AF.  
 
Conclusion 
In conclusion, this analysis has  demonstrated that a prolonged QT interval, which is 
a simple ECG marker commonly used in clinical practice, is able to identify patients 
with AF in an “all comer” population of patients presenting to a typical district general 
hospital in the United Kingdom.  
The predictive value of prolonged QT interval is independent of clinical variables, 
possibly reflecting a distinctive mechanism of AF generation and maintenance.  
Therefore, a combined model of simple clinical risk factors and simple ECG 
markers may be a useful tool to be used in routine clinical practice to predict the risk 
of AF. Our findings invite larger studies to validate these findings further.  
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Table 7. Demographics of PAF and sinus rhythm patients 
 Sinus rhythm 
(n= 341) 
Paroxysmal AF 
(n=153) 
p-value 
Age (+/- SD) 66 (+/- 11.5) 70 (+/- 12) 0.001 
Gender  (%) 62 62 0.523 
eGFR (+/- SD) 62 (+/- 27.6) 49 (+/- 32.9) <0.001 
BMI (+/- SD)  30 (+/- 9.6) 30 (+/- 7) 0.98 
Hypertension (%) 67 56 0.009 
Coronary artery disease (%)  48 20 <0.001 
Diabetes (%) 42 18 <0.001 
Stroke or TIA (%) 11 7 0.103 
Heart failure (%) 11 9 0.234 
Simple ECG markers    
PR interval ms (+/- SD) 172 (+/- 34.5) 175 (+/- 43.3) 0.369 
QRS interval ms (+/- SD) 97 (+/- 24.3) 101 (+/- 27.9) 0.120 
QT interval ms (+/- SD) 395 (+/- 46.3) 406 (+/- 50) 0.016 
QTc interval ms (+/- SD) 434 (+/- 36.2) 433 (+/- 47) 0.717 
Complex markers     
P wave duration ms (+/- SD) 104.8 (21.5) 109 (+/- 29.7) 0.103 
 
 107 
P wave dispersion ms (+/- SD) 0.501 (+/- 2.92) 0.68 (+/- 3.33) 0.619 
PQ time ms (+/- SD) 171 (+/- 37.4) 176 (+/- 41.6) 0.376 
P wave mean area (+/- SD) 3.1 (+/- 1.13) 2.98 (+/- 1.22) 0.339 
P wave amplitude (+/- SD) 0.08 (+/- 0.02) 0.09 (+/- 0.076) 0.171 
 
 
Table 8 - Logistic regression model using simple ECG markers 
 
B (+ve predicts 
AF) S.E. Wald df Sig. Exp(B) 
PQ duration (ms) 0.02 0.003 0.365 1 0.546 1.002 
QRS duration (ms) 0.005 0.005 1.163 1 0.281 1.005 
QT duration (ms) 0.006 0.003 4.857 1 0.028 1.006 
 
Table 9 – Logistic regression model using complex ECG markers 
 
B (+ve predicts 
AF) S.E. Wald df Sig. Exp(B) 
P wave duration  
(ms) 
0.019 0.007 7.184 1 0.007 1.020 
P wave dispersion  0.017 0.038 0.206 1 0.650 1.017 
PQ time  (ms) -0.000065 0.004 0.000259 1 0.987 1 
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P Wave Mean Area  -0.739 1.147 0.415 1 0.520 0.478 
P Wave Amplitude  
(mV) 
8.83 39.1 0.051 1 0.821 6866 
 
Table 10 – Logistic regression model using combined simple and complex ECG 
(denoted by *) markers 
 
 
 
 
 B (+ve 
predicts 
AF) 
SE Wald Df Sig. Exp (B) 
 P wave duration * (ms) 0.014 0.008 3.129 1 0.077 1.015 
P wave dispersion *  0.016 0.039 0.168 1 0.682 1.016 
PQ time * (ms) 0.003 0.005 0.122 1 0.726 1.002 
P Wave Mean Area *  -1.054 1.263 0.696 1 0.404 0.349 
P Wave Amplitude * 
(mV) 
6.11 52.45 0.014 1 0.907 450.324 
QRS duration (ms) 0.002 0.006 0.076 1 0.782 1.002 
PQ duration (ms) 0.0004 0.004 0.011 1 0.916 1 
QT duration (ms) 0.011 0.003 9.523 1 0.002 1.011 
Constant -7.678 1.755 19.147 1 <0.001 0.005 
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 Table 11 – Combined logistic regression model using relevant ECG markers and 
clinical risk factors.  
 
  
 B (+ve 
predicts 
AF) 
SE Wald Df Sign Exp (B) 
Stroke or TIA -0.516 0.446 1.343 1 0.246 0.597 
Hypertension -0.766 0.259 8.77 1 0.003 0.465 
Heart failure -0.566 0.445 1.583 1 0.208 0.571 
Coronary artery 
disease 
-1.397 0.291 23.08 1 <0.001 0.247 
Diabetes -1.344 0.293 20.79 1 <0.001 0.263 
Gender (M) 0.322 0.264 1.49 1 0.223 1.379 
eGFR -.007 0.007 1.065 1 0.302 0.993 
BMI 0.045 0.02 5.058 1 0.025 1.046 
Age 0.027 0.012 4.99 1 0.025 1.028 
QT duration (ms) 0.007 0.003 7.221 1 0.007 1.007 
Constant -5.246 1.774 8.74 1 0.003 0.005 
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Chapter 6:  Results 
Investigating the use of a combined model using clinical variables, 
ECG markers and blood based biomarkers in the prediction of AF 
Introduction 
From the results in Chapter 4 and 5, it has been  established that there are significant 
differences in blood based biomarkers (FGF-23 and BNP) and simple ECG marker 
such as prolonged QT interval between AF and sinus rhythm patients. FGF-23 and 
BNP are independently associated with AF in a multivariable model consisting of 
clinical risk factors. QT interval is also independently associated with AF when 
analysed in a model combined with clinical risk factors.  
Increased BNP is likely to reflect pressure overload in the cardiac chambers and heart 
failure as a driving mechanism for AF. FGF-23 on the other hand, is likely to reflect 
cardiac stiffness as a potential mechanism.  
Referring back to Figure 3 in Chapter 1 which outlined the potential 4 separate but 
interlinked mechanisms causing AF, BNP is likely to be reflecting the 
haemodynamic loop and FGF-23 representing the structural loop. Increased QT 
interval is likely to be a marker of the altered electrical and trigger loops which also 
contribute to AF.  
In the current literature, there are three scoring systems which have been developed 
to predict the occurrence of incident AF (Framingham Heart Study, Atherosclerosis 
Risk in Communities Study and CHARGE-AF study). 
As previously mentioned in Chapter 1, these scoring systems consisted primarily of a 
combination of clinical and ECG markers except the CHARGE-AF study which 
included clinical variables only. BNP improved the ability of the model to predict 
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incident AF when added to the Framingham Heart Study scoring system. Some of the 
clinical parameters employed in these scoring systems are somewhat subjective such 
as clinically significant cardiac murmur in the Framingham Heart Study.  
There are no large studies in the current literature which systematically derived an AF 
prediction model based on a combination of clinical variables, simple ECG parameters 
and blood based biomarkers using a novel proteomics technique. 
In order to explore this new concept, data from the previous 2 results (Chapters 4 and 
5) chapters were used to establish a model consisting of clinical, ECG and blood 
based biomarkers to investigate if these markers independently predict AF in a 
combined model.  
Aims 
To establish a model consisting of clinical markers, simple ECG parameters and 
blood based biomarkers to predict prevalent AF.   
Hypothesis 
As outlined in the two previous results chapters, it has been established that blood 
based biomarkers and ECG markers act as markers for different but linked loops in 
AF generation and maintenance.  
The hypothesis therefore is that a combined model using clinical, ECG and blood 
based biomarkers would demonstrate that all of these three separate but linked 
biomarkers are independently associated with AF.  
 
Methods 
Patient recruitment methods along with inclusion/exclusion criteria for this study 
have been previously described in Chapter 2. As previously mentioned, both  
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Cardiovascular Panel 1 and 2 were used for analysis of different batches due to 
discontinuation of Cardiovascular Panel 1 production during the course of the study. 
Therefore, analysis will be done separately for each cardiovascular panel due to assay 
differences between the different biomarker panels.  
Logistic regression methods will be used to construct various models for prediction 
of AF from data from each panel:  
a) clinical variables only, 
 b) simple / complex ECG variables only,  
c) Combined simple and complex ECG variables.  
d) blood based biomarkers only.  
An overall model will then be constructed for each panel combining clinical 
parameters, ECG parameters and biomarkers. ROC curves will also be generated for 
each of the separate models for both Cardiovascular panel 1 and 2 to illustrate the 
predictive ability of these models.  
It must be highlighted that patients identified as AF in this results chapter consist of 
patients who have paroxysmal AF whose ECG showed sinus rhythm at the time of 
enrolment. The reason for using this particular subset of AF patients is because the 
ECGs for this patient cohort has been analysed for specific parameters such as P wave 
parameters which are only available in patients in sinus rhythm.  
Patients who are known to have persistent AF or were in AF at the time of recruitment 
cannot have P wave simple or complex parameters analysed and therefore they were 
excluded from this combined analysis. The patient numbers in the derivation and 
validation cohorts are therefore different compared to previous results chapters.  
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Results 
Cardiovascular Panel 1  
296 patients were included in the analysis from Cardiovascular Panel 1. The baseline 
characteristics of patients from Cardiovascular Panel 1 are shown in Table 12.  In terms 
of clinical characteristics, AF patients were older (69 vs 66 years old p=0.06) but had 
significantly less diabetes and coronary artery disease. There was no significant 
difference in FGF-23 (3.76 vs 3.56 p=0.22) and BNP (2.71 vs 2.28 p=0.09) levels between 
AF and sinus rhythm patients. There was no significant difference between complex 
or simple ECG markers between the AF and sinus rhythm groups.  
Models using logistic regression were then constructed. Using clinical variables (age, 
gender, BMI, stroke, hypertension, heart failure, coronary artery disease and diabetes) 
only, male gender predicted AF whereas diabetes and coronary artery disease both 
predicted sinus rhythm (Table 13).  
Using simple ECG parameters, QRS duration was an independent predictor for AF 
(Table 14). There were no independent predictors of AF when complex ECG 
parameters were used.  
A model combining simple and complex ECG variables (Table 15) found that QT 
duration independently predicted AF (OR 1.015 per ms increase in QT duration 
p=0.019).  
FGF-23 and BNP did not independently predict AF in a model consisting of blood 
based biomarkers only (Table 16).  
An overall model (Table 17) combining clinical parameters, ECG parameters and 
blood based biomarkers found that male gender, prolonged QT interval and higher 
FGF-23 levels were independent predictors of AF. BNP was not an independent 
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predictor for AF in the combined model for Cardiovascular Panel 1. Coronary artery 
disease and diabetes were independent predictors for sinus rhythm.  
ROC curves were created to demonstrate the predictive ability of these various models 
(Figures 10-13).  
As demonstrated in Figure 10 and 11, a model consisting of clinical variables only has 
a good predictive ability compared to the fair predictive ability if the model consists 
of ECG markers only. Biomarkers (FGF-23 and BNP) model on its own has a poor 
predictive ability for AF.  
However, a model consisting of a combination of the clinical parameters, ECG 
parameters and blood based markers has an even better ability to predict AF 
compared to a model consisting of clinical variables only. A summary of the AUC for 
the various models is shown in Table 24. 
Table 12. Baseline characteristics of patients Cardiovascular Panel 1 
 Sinus rhythm 
(n=212)  
AF (n= 84) p-value 
Clinical variables    
 Age  (+/- SD) 66 +/- 12 69 +/- 12 0.058 
Male  (%) 128 ( 60.4%) 57 (68%) 0.287 
BMI (+/- SD) 29.6 29.6 0.97 
Stroke (n) (%) 23 (10.8%) 6 (7.1%) 0.392 
Hypertension (n) (%) 140 (66%) 52 (62%) 0.294 
Heart failure (n) (%) 30 (14.2%) 9 (10.7%) 0.568 
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Coronary artery disease (n) 
(%) 
85 (40.1%) 12 (14.3%) <0.0001 
Diabetes (n) (%) 88 (41.5%) 14 (16.7%) <0.0001 
eGFR (+/- SD) 68.1 (+/- 20.4) 67.5 (+/- 18.7) 0.814 
Blood based biomarkers    
FGF-23 (+/- SD) 3.56 (+/- 1.18) 3.76 (+/- 1.49) 0.216 
BNP (+/- SD) 2.28 (+/- 1.95) 2.71 (+/- 1.98) 0.087 
ECG markers    
Simple ECG parameters    
PR interval (+/- SD) 171.3 (+/- 36.0) 175.3 (+/- 45.2) 0.48 
QRS interval (+/- SD) 93.1 (+/- 18.6) 98.6 (+/- 25.1) 0.04 
QT duration (+/- SD) 393.62 (+/- 
43.4) 
401.33 (+/- 47.2) 0.19 
QTc duration (+/- SD) 431.76 (+/- 
34.65) 
433.43 (+/- 35.22) 0.714 
Complex ECG parameters    
P Wave duration (+/- SD) 104 (+/- 22.4) 105 (+/- 28.5) 0.926 
P Wave dispersion (+/- SD) 0.855 (+/- 3.83) 2.11 (+/- 5.67) 0.129 
PQ time (+/- SD) 169.88 (+/- 
37.67) 
168.96 (+/- 45.11) 0.906 
 
 116 
P wave mean area (+/- SD) 1.18 (+/- 0.56) 1.26 (+/- 0.68) 0.765 
P wave amplitude (+/- SD) 0.025 (+/- 
0.101) 
0.028 (+/- 0.015) 0.093 
 
Table 13. Logistic regression model Cardiovascular Panel 1 – clinical variables only. 
 
 B S.E. Wald df Sig. Exp(B) 
 BMI .003 .013 .062 1 0.803 1.003 
Age .019 .013 2.221 1 0.136 1.019 
Gender (male) .766 .318 5.795 1 0.016 2.151 
Stroke or TIA -.658 .518 1.613 1 0.204 .518 
Hypertension -.209 .310 .454 1 0.501 .812 
Heart failure -.320 .476 .453 1 0.501 .726 
Coronary artery 
disease 
-1.870 .391 22.856 1 <0.001 .154 
Diabetes -1.731 .368 22.130 1 <0.001 .177 
Constant -1.602 1.104 2.106 1 0.147 .201 
 
Table 14. Logistic regression model Cardiovascular Panel 1 – simple ECG markers 
only 
 
 
B S.E. Wald df Sig. Exp(B) 
 QRS duration (ms) .020 .008 5.544 1 0.019 1.020 
PQ duration (ms) .001 .004 .028 1 0.867 1.001 
 
 117 
QT duration (ms) .005 .004 1.963 1 0.161 1.005 
QTC calculated (ms) -.005 .005 .850 1 0.357 .995 
Constant -3.229 2.144 2.268 1 0.132 .040 
 
Table 15. Logistic regression model Cardiovascular Panel 1 – combined simple 
and complex* ECG markers. 
 
 
Table 16. Logistic regression model Cardiovascular Panel 1 – blood based 
biomarkers only.  
 B S.E. Wald df Sig. Exp(B) 
FGF-23 .068 .104 .430 1 0.512 1.071 
 B SE Wald Df Sign Exp (B) 
 P wave duration * (ms) .002 .015 .025 1 0.874 1.002 
P wave dispersion *  .052 .049 1.121 1 0.290 1.053 
PQ time * (ms) .003 .009 .113 1 0.737 1.003 
P Wave Mean Area *  -.738 1.899 .151 1 0.698 .478 
P Wave Amplitude * 
(mV) 
-119.758 104.320 1.318 1 0.251 .000 
QRS duration (ms) .014 .013 1.205 1 0.272 1.014 
PQ duration (ms) .001 .008 .005 1 0.943 1.001 
QT duration (ms) .015 .006 5.476 1 0.019 1.015 
QTc duration (ms) -.006 .007 .702 1 0.402 0.994 
Constant -8.145 3.637 5.015 1 0.025 .000 
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F
G
F
- 
BNP .094 .069 1.836 1 0.175 1.098 
Constant -1.409 .384 13.485 1 .000 .244 
 
Table 17. Combined logistic regression model including clinical variables, 
relevant ECG markers and blood based biomarkers.  
 
B (+ve 
predicts AF)  S.E. Wald df Sig. Exp(B) 
 FGF-23 .513 .184 7.788 1 0.005 1.671 
BNP .086 .100 .743 1 0.389 1.090 
QT duration (ms) .008 .004 3.891 1 0.049 1.008 
BMI .028 .027 1.057 1 0.304 1.028 
Age .014 .017 .745 1 0.388 1.014 
eGFR .018 .011 2.418 1 0.120 1.018 
Gender (male) 1.098 .406 7.302 1 0.007 2.999 
Stroke or TIA -.478 .588 .661 1 0.416 .620 
Hypertension -.102 .371 .075 1 0.784 .903 
Heart failure -1.136 .607 3.504 1 0.061 .321 
Coronary artery disease -2.196 .485 20.471 1 <0.001 .111 
Diabetes -1.864 .441 17.896 1 <0.001 .155 
Constant -8.758 2.846 9.473 1 .002 .000 
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Figure 10: ROC curve Cardiovascular Panel 1 – clinical variables only 
 
 
Figure 11: Cardiovascular Panel 1 – ECG markers only (simple and complex 
markers combined).  
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Figure 12: Cardiovascular Panel 1 – blood based biomarkers only (BNP and FGF-
23) 
 
Figure 13: Cardiovascular Panel 1 (combined clinical, ECG and blood based 
biomarkers) 
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Cardiovascular Panel 2 
198 patients were included in the analysis from Cardiovascular Panel 2. The baseline 
demographics of this cohort are described in Table 18.  
AF patients were older (72 vs 67 p=0.004) and had worsening renal function (eGFR 70 
vs 62 p <0.006) compared to sinus rhythm patients. There was a significantly higher 
proportion of diabetes, coronary artery disease and hypertension in sinus rhythm 
patients. Patients with AF had a higher level of FGF-23 (3.81 vs 3.44 p=0.05) and BNP 
(2.99 vs 1.97 p=0.01) compared to sinus rhythm patients. Patients in the AF group had 
a longer QT interval compared to the sinus rhythm cohort (414 vs 397 p=0.04).  
 A logistic regression model using clinical variables only (Table 19) showed that 
hypertension, coronary artery disease and diabetes as well as eGFR were independent 
predictors of AF.  
There were no independent simple ECG markers independently predictive of AF. P 
wave duration was independently predictive of AF (OR 1.024 p=0.04) in a model 
comprising complex ECG variables only (Table 20).  
In a model combining complex and simple ECG markers (Table 21), QT interval 
remained independently predictive for AF (OR 1.017 p=0.017). In a model consisting 
of blood based biomarkers only, BNP but not FGF-23 remained an independent 
predictor of AF (OR 1.270 p=0.04) (Table 22).  
An overall model combining clinical, ECG and blood based biomarkers (Table 23) 
showed that hypertension, coronary artery disease, diabetes and eGFR independently 
predicted sinus rhythm whereas BNP and prolonged QT interval independently 
predicted AF. Fibroblast growth factor 23 did not independently predict AF in this 
combined model.  
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ROC curves were created for the various models to compare their ability to accurately 
discriminate patients who have AF as demonstrated by Figures 14-17.  
Models using clinical variables only had a similar fair predictive ability compared to 
models using ECG parameters only (AUC 0.79 and 0.78 respectively). A model using 
the blood based biomarkers only (FGF-23 and BNP) had a poor predictive ability.  
However, the predictive ability of the model improved significantly and 
demonstrated good predictive ability when clinical, ECG and blood based biomarkers 
were combined. A summary of the predictive ability of the various models across both 
cardiovascular panels is illustrated in Table 24.  
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Table 18. Demographics of cohort analysed using Cardiovascular Panel 2 
 Sinus rhythm 
(n=129)  
AF (n= 69) p-value 
Clinical variables    
 Age  (+/- SD) 67 (+/- 111) 72 (+/- 12) 0.003 
Male  (%) 83 (64) 38 (55) 0.131 
BMI (+/- SD) 30 (+/- 6.3) 30 (+/- 6.5) 0.94 
Stroke (n) (%) 13 (10) 4 (6) 0.228 
Hypertension (n) (%) 89 (69) 33 (48) 0.003 
Heart failure (n) (%) 8 (6) 4 (6) 0.589 
Coronary artery disease 
(n) (%) 
78 (61) 18 (26) <0.001 
Diabetes (n) (%) 56 (43) 14 (20) 0.001 
eGFR (+/- SD) 70 (+/- 16) 62 (+/- 21)  0.006 
Blood based biomarkers    
FGF-23 (+/- SD) 3.44 (+/- 
1.15) 
3.81 (+/-1.49) 0.05 
BNP (+/- SD) 1.97 (/- 1.86) 3 (+/- 2.11) 0.001 
ECG markers    
Simple ECG markers    
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PR interval (+/- SD) 177 (+/- 34) 175 (4+/- 43.9) 0.795 
QRS interval (+/- SD) 101 (+/- 28.4) 103 (+/- 29.7) 0.532 
QT duration (+/- SD) 397 (+/- 50.2) 414 (+/- 56.6) 0.036 
QTc duration (+/- SD) 434 (+/- 38) 436 (+/- 58) 0.891 
Complex ECG markers    
P Wave duration (+/- 
SD) 
109 (+/- 20.5) 116 (+/- 27.2) 0.091 
P Wave dispersion (+/- 
SD) 
0 0  
PQ time (+/- SD) 177 (+/- 37.7) 179 (+/- 40.8) 0.771 
P wave mean area (+/- 
SD) 
3.17 (+/- 
0.932) 
2.93 (+/- 1.05) 0.166 
P wave amplitude (+/- 
SD) 
0.08 (+/- 
0.017) 
0.077 (+/- 0.021) 0.343 
 
Table 19. Logistic regression model with clinical variables only 
(Cardiovascular Panel 2) 
 
B (+ve predicts 
AF) S.E. Wald df Sig. Exp(B) 
 BMI .045 .035 1.637 1 0.201 1.046 
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Age .030 .020 2.275 1 0.131 1.030 
eGFR -.023 .011 4.146 1 0.042 .977 
Gender (male) -.309 .414 .558 1 0.455 .734 
Stroke or TIA -.771 .749 1.057 1 0.304 .463 
Hypertension -1.456 .409 12.641 1 <0.001 .233 
Heartfailure -.114 .801 .020 1 0.887 .892 
Coronary artery disease -.983 .421 5.439 1 0.020 .374 
Diabetes -.993 .455 4.771 1 0.029 .370 
Constant -.897 2.476 .131 1 0.717 .408 
 
 
 
 
B (+ve 
predicts AF) S.E. Wald df Sig. Exp(B) 
 P Wave Duration  .023 .012 4.161 1 0.041 1.024 
PQ time -.005 .007 .563 1 0.453 .995 
P Wave Mean Area -.952 1.950 .238 1 0.625 .386 
P Wave Amplitude 14.104 73.392 .037 1 0.848 1334540 
Constant -2.215 1.709 1.679 1 0.195 .109 
Table 20. Logistic regression model – complex ECG markers only (CV Panel 2) 
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Table 21. Logistic regression model – combined simple and complex* ECG markers. 
(Cardiovascular Panel 2) 
 
B (+ve 
predicts AF) S.E. Wald df Sig. Exp(B) 
 P Wave Duration* .009 .017 .306 1 0.580 1.009 
PQ time* -.003 .010 .082 1 0.775 .997 
P Wave Mean Area* -2.612 2.528 1.068 1 0.301 .073 
P Wave Area* -.764 2.479 .095 1 0.758 .466 
P Wave Amplitude*  -25.110 92.364 .074 1 0.786 .000 
QRS duration .001 .011 .006 1 0.941 1.001 
PQ duration -.001 .006 .034 1 0.854 .999 
QT duration .017 .007 5.794 1 0.016 1.017 
QTc duration -.008 .009 .723 1 0.395 .992 
Constant -4.975 3.755 1.755 1 0.185 .007 
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Table 22. Logistic regression model – blood based biomarkers only 
(Cardiovascular Panel 2) 
 B S.E. Wald df Sig. Exp(B) 
 BNP .239 .082 8.447 1 0.004 1.270 
FGF-23  .098 .124 .626 1 0.429 1.103 
Constant -1.569 .460 11.631 1 .001 .208 
 
 
Table 23. Combined logistic regression model including clinical variables, 
relevant ECG markers and blood based biomarkers 
(Cardiovascular Panel 2) 
 B S.E. Wald df Sig. Exp(B) 
 eGFR -.020 .012 2.519 1 0.112 .980 
Coronary artery disease -1.123 .452 6.183 1 0.013 .325 
Hypertension -1.504 .448 11.252 1 0.001 .222 
Diabetes -1.036 .490 4.463 1 0.035 .355 
BMI .066 .039 2.768 1 0.096 1.068 
Age .027 .021 1.702 1 0.192 1.028 
Gender (male) -.423 .450 .884 1 0.347 .655 
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Figure 14: Cardiovascular Panel 2 – clinical variables only
 
 
 
 
Stroke or TIA -.868 .792 1.200 1 0.273 .420 
Heart failure -.716 .862 .690 1 0.406 .489 
QT duration (ms) .009 .004 5.609 1 0.018 1.009 
FGF-23 -.070 .173 .162 1 0.687 .933 
BNP .307 .113 7.423 1 0.006 1.359 
Constant -5.717 3.100 3.402 1 .065 .003 
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Figure 15: Cardiovascular Panel 2 – ECG variables only 
 
 
Figure 16: Cardiovascular Panel 2 – blood based biomarkers only 
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Figure 17: Cardiovascular Panel 2 – combined clinical/ECG/blood based biomarkers 
  
Table 24: Summary of the ability of various models to predict AF 
 Cardiovascular Panel 1 
(AUC) 
Cardiovascular Panel 2 
(AUC) 
Clinical variables only 0.78 0.79 
ECG variables only 
(simple and complex 
markers combined) 
 
0.72 
 
0.78 
Blood based biomarkers 
only (FGF-23 and BNP) 
 
0.58 
 
0.65 
Combined model 
(clinical, ECG and blood 
based markers) 
 
0.81 
 
0.84 
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Discussion 
Our study investigating the predictive ability of a model including blood based 
biomarkers, ECG markers and clinical markers in 2 cohorts has generated important 
findings.  
Cardiovascular Panel 1  
1) In a model derived from the Cardiovascular Panel 1 consisting of clinical 
variables only, male sex was an independent predictor of AF whereas diabetes 
and coronary artery disease independently predicted sinus rhythm. Our results 
are consistent with previous studies which have demonstrated association of 
male gender with AF. The exact reasons for the increased risk of AF in males is 
not entirely clear but it has been proposed that men and some post-menopausal 
women have longer atrial refractory periods compared to premenopausal 
women which can predispose to AF. It has also been suggested by some studies 
that differences in ion channel expression between males and females as well 
as differences in autonomic control of cardiac electrical activity may explain at 
least some of the gender related differences.  
 
Diabetes and coronary artery disease have been typically been recognised as 
risk factors for AF rather than sinus rhythm. In our cohort however, these are 
likely to be associated with sinus rhythm because of the recruitment criteria in 
the sinus rhythm group. As previously mentioned in the recruitment criteria, 
patients needed to have certain cardiac risk factors before being included in the 
sinus groups whereas the presence of such risk factors was not a recruitment 
criterion for AF patients to be enrolled. Therefore, significantly more patients 
in the sinus rhythm groups have coronary artery disease and diabetes due 
compared to the AF group.  
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2) Longer QT interval was associated with an increased risk of AF in a model 
consisting of simple and complex ECG markers. This is consistent with 
previous studies which have demonstrated that increased QT interval is 
associated with incident AF. There are various theories which have been 
proposed to explain the increased risk of AF associated with prolonged QT 
interval.  It is possible that increased QT interval may reflect an increased 
propensity to AF as a manifestation of irregularities in refractoriness in both 
atria and ventricles. Other studies suggest that a prolonged QT interval may 
reflect enhanced activity of the late sodium current which manifests as a 
prolonged QT on the ECG. This enhanced sodium activity increases the 
intracellular calcium which can lead to AF via triggered automaticity 
mechanisms.  
 
3) In a combined model of clinical/biomarkers/ECG markers, male gender, 
increased QT interval and increased FGF-23 levels are associated with 
increased risk of AF.  
BNP was not associated with AF in the model. Coronary artery disease and 
diabetes independently predicted SR. As elucidated in point 1 of the 
discussion, the ability of coronary artery disease and diabetes to predict sinus 
rhythm is likely to represent the recruitment profile of the sinus rhythm cohort. 
Male gender is an independent risk factor for AF and is likely to represent 
differences in atrial effective refractory periods, differences in ion channel 
expression and also differences in autonomic control. QT interval also 
independently predicts AF with the likely mechanisms outlined in point 2 of 
discussion. FGF-23 independently predicts AF though mechanisms outlined in 
Chapter 3 i.e. myocardial remodelling, cardiac hypertrophy with an increase in 
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ectopic activity and automaticity.  
 
Overall, in this cohort, this combined model consisting of three independent 
predictors of AF (male gender, QT interval and FGF-23) are likely to represent 
surrogate markers of three loops of the various mechanisms driving AF as 
outlined in Figure 3 in Chapter 1. Male gender and QT interval are likely to 
represent the electrical and trigger loops with FGF-23 a marker of the structural 
loop.  
 
The reason why BNP is not an independent predictor of AF in this model is not 
entirely clear. Our sinus rhythm cohort had a higher proportion of patients 
with heart failure compared to the AF cohort even though this difference was 
not statistically significant. BNP may therefore be higher in certain subgroups 
of the sinus rhythm cohort compared to the AF cohort and therefore the 
predictive ability of BNP specifically for AF may be dampened.  
 
It is therefore plausible that in patient cohorts where clinical conditions such as 
heart failure are more prevalent, the clinical risk factors play a greater role in 
AF causation. The blood based biomarkers such as BNP in this case, “cancel 
out” when the model includes these important clinical risk factors.  
 
In situations where the clinical risk factors such as heart failure are less 
apparent, then blood based biomarkers may play a more important role as 
independent predictors of AF.  
The other possibility is that in this cohort, the effect of heart failure is less in 
driving AF and the predominant factor is the profibrotic pathway in the 
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structural loop as demonstrated by the independent predictive ability of FGF-
23.  
Cardiovascular Panel 2. 
1) In a model comprising of clinical variables only, hypertension, coronary artery 
disease, diabetes were predictive of sinus rhythm. Lower eGFR predicted AF 
independently. The association of hypertension, coronary artery disease and 
diabetes is likely to reflect the recruitment profile of the sinus rhythm patients 
who have a higher proportion of these clinical characteristics compared to the 
AF cohort. The ability of worsening renal function to predict AF is consistent 
with results from the current literature where patients with worsening renal 
function had higher risk of developing AF.  
It appears that there is a close intertwined relationship between CKD and AF 
with some suggestion that this may be because of shared common risk factors. 
There are also other suggestions implicating FGF-23, which is found in greater 
quantities in patients with CKD and FGF-23 is already known to have cardiac 
consequences such as cardiac remodelling.  
2) In a model combining simple and complex ECG markers, longer QT interval 
was an independent predictor of AF. This is consistent with results from 
current literature with potential mechanisms of AF causation outlined 
previously in this chapter.  
3) In a combined model consisting of clinical/ECG/blood based biomarkers, 
coronary artery disease, hypertension, diabetes and improving renal function 
independently predicted sinus rhythm.  
 
As previously mentioned, this relationship is likely due to the recruitment 
profile of the sinus rhythm patients who needed to have certain clinical 
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characteristics such as coronary artery disease, hypertension and diabetes for 
example before being recruited. The AF patients did not require any extra 
clinical characteristics before being recruited.  
 
BNP and QT independently predicted AF whereas FGF-23 did not. The ability 
of BNP to independently predict AF has already been established in previous 
studies and our results are consistent with this. Elevated BNP levels predicting 
AF are likely to represent the haemodynamic loop of AF 
initiating/maintenance mechanisms. A prolonged QT interval as an 
independent predictor of AF is likely to represent the electrical/trigger loops.  
 
 Interestingly, FGF-23 was not independent predictor of AF in this analysis. The 
reasons for this are not entirely clear. The role of FGF-23 in AF is still not 
entirely clear with some studies linking higher FGF-23 level to AF whereas 
others not finding a link. It is possible that other mechanisms other than fibrosis 
such as haemodynamic and electrical loops play a greater role in this cohort 
and therefore the ability of FGF-23 to predict AF is limited.  
 
Another possibility is that there is a higher proportion of hypertensives in the 
sinus group compared to the AF cohort. Sustained uncontrolled hypertension 
can cause left ventricular hypertrophy and increased cardiac stiffness with 
subsequent AF generation because of structural and haemodynamic 
abnormalities. FGF-23 can also cause adverse cardiac remodelling and 
contribute to AF generation through a similar mechanism.  
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It therefore appears that the clinical risk factors play a more important role in 
predicting AF compared to the blood based biomarkers. Blood based 
biomarkers become useful independent predictors of AF in cohorts where the 
clinical risk factors are less prevalent.  
 
Analysis of the predictive ability of the models across both Cardiovascular Panel 1 
and 2 have generated similar observations. Models including clinical variables only 
have a fair ability to discriminate AF. Models including ECG variables only also 
display a fair ability to discriminate AF but less so than clinical variables model. 
Biomarker models on their own have a poor predictive ability for AF.  
The real strength of the models becomes apparent when the clinical, ECG markers and 
biomarkers are combined and this generates a model with good predictive ability for 
discriminating AF. This observation is consistent with our logistic regression results 
and consolidates the fact that clinical variables do play a major role in prediction of 
AF.  
However, other mechanisms of AF generation such as trigger and electrical loops also 
play a separate although linked role and therefore ECG markers also display fair 
predictive ability.  
The combined model displays a higher predictive ability compared to the all the 
individual models; this may be consistent with the fact that AF has a multifactorial 
aetiology and the various components in our model reflect a significant proportion of 
those factors.  
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Clinical implications 
As outlined in Chapter 1, there is a significant proportion of patients with AF who do 
not have any obvious risk factors and therefore screening using markers of 
pathophysiological mechanisms rather than clinical risk factors only may be more 
sensitive in detecting patients with silent AF and patients at risk of AF.  
Our model derived from these two cohorts consists of simple clinical demographics, 
simple ECG parameters and 2 blood based biomarkers (one novel and one 
established).  
It appears that in patients with established clinical risk factors for AF, these risk 
factors play a more major role in the prediction of AF compared to blood based 
biomarkers. For example, in cohorts where there are higher proportion of heart failure 
patients (more heart failure patients in Panel 1 compared to Panel 2), the strength of 
BNP in predicting AF is reduced.  
Conversely, in populations where the proportion of heart failure is less, the role of 
BNP becomes more important, as highlighted by the results from the Panel 2 cohort.  
The same situation seems to be applicable to FGF-23. In populations where there are 
clinical risk factors causing similar pathophysiological mechanisms leading to AF 
such as hypertension causing LVH and cardiac remodelling, FGF-23 becomes a 
weaker marker for AF in those models. In Panel 1, there is a lower proportion of 
hypertensives compared to Panel 2 and in this case, the predictive ability of FGF-23 
becomes more apparent.  
In clinical practice therefore, our study results propose that an AF prediction model 
should include all the simple clinical risk factors outlined in this analysis, QT 
interval and both FGF-23 and BNP.  
 
 138 
In cohorts where clinical risk factors are in high proportion, the biomarkers FGF-
23/BNP will play a smaller role. However, in patient cohorts where there are fewer  
clinical risk factors, FGF-23 and BNP are likely to play a more significant role. 
 Our combined model consists of biomarkers potentially acting as surrogate markers 
for and reflecting all the 4 known major loops in AF generation/maintenance 
outlined previously in Chapter 1.  
To our knowledge, this is the first model of its kind to include parameters reflecting 
all the major loops and therefore is more likely to detect patients with silent AF/ at 
risk of AF.  
 
Limitations 
This is a cross-sectional study and includes patients with prevalent, not incident AF. 
There will be follow up data at two years and therefore the model can then be 
validated prospectively. The biomarker panels also measure relative rather than 
absolute protein concentrations and therefore larger, more diverse studies are invited 
to validate this current model to detect incident AF.  
Conclusion 
This analysis across two separate cohorts has identified elevated BNP, elevated FGF-
23, prolonged QT interval and male gender as independent predictors of AF in 
combined models. FGF-23 has been identified as a new independent biomarker for 
AF. Blood based biomarkers play a smaller role in predicting AF in cohorts where 
there is a higher prevalence of clinical risk factors; prolonged QT interval remains an 
independent predictor irrespective of clinical risk factors.  A simple model combining 
these clinical and blood based parameters could have useful implications for detecting 
AF in patients without any major risk factors.  
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Addendum to Chapter 6 
Harmonising data for Cardiovascular Panel 1 and 2? 
As previously mentioned, we used two different Cardiovascular Panels for biomarker 
analysis in the study. The initial Cardiovascular Panel 1 was the original planned 
panel to be used for the entire study. However, the Olink company ceased production 
of this specific panel around 1 year after our study started and split the initial 
biomarker profile of Cardiovascular Panel 1 into two separate new panels 
(Cardiovascular Panel 2 and Cardiovascular Panel 3).  
Based on our pilot data which we had analysed using Cardiovascular Panel 1, we had 
already identified two biomarkers which were independently predictive of atrial 
fibrillation (BNP and FGF-23). Based on this pilot data, we then decided to continue 
our biomarker analysis of the remainder of our cohort using Cardiovascular Panel 2 
which contained BNP and FGF-23. Due to the inherent differences between the 
Cardiovascular Panel 1 and 2, we felt that it would be best to analyse and derive 
models for AF prediction for the different panels separately with the results outlined 
in this chapter. At the time of the initial analysis, we double-checked the possibility of 
harmonising data across the panels with the Olink team and they advised that it 
would be best to analyse both separately.  
Following discussion at the Thesis review panel in July 2019, the prospect of 
harmonising data across both panels was reconsidered especially given the possibility 
the company may now have developed further expertise after a few years in terms of 
harmonising data.  
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Following email contact with Olink Proseek, it became apparent there is still no 
conventional established way of cohesively analysing data from 2 biomarker panels. 
One possible way of harmonising the data as suggested by the Olink team was to 
execute the logistic regression model with the entire cohort (Panel 1 and 2) but to also 
include the biomarker panel (1 or 2) as covariate in the model. However, due to the 
novelty of this biomarker analysis technique, this method of combining data from 2 
biomarker sets remains non-standardised and unvalidated in large studies. While 
they suggested that combining the data using biomarker panel data for the logistic 
regression only, I was advised that combining the biomarker data for other analyses 
(such as mean FGF-23 / BNP levels combined across both samples) would not be 
accurate or valid. Therefore, I only present the data of the combined biomarker 
analysis in the logistic regression model below.  
Binary logistic regression was therefore performed using conventional methods as 
described earlier in this Chapter and in the Methods Chapter with the addition of 
biomarker panel as an additional covariate.  
Results 
The results of logistic regression model for the entire cohort is shown below in Table 
25. In this model, BNP, BMI and QT interval independently predicted AF whereas 
FGF-23 did not. Hypertension, coronary artery disease and diabetes independently 
predicted sinus rhythm.  
Table 25. Combined logistic regression model using clinical variables, relevant 
ECG markers and blood based biomarkers for entire cohort (Cardiovascular Panel 
1 and 2) 
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 B (+ve 
predicts 
AF) 
S.E Wald Df Sig. Exp (B) 
BNP 0.188 0.071 7.013 1 0.008 1.207 
FGF-23 0.203 0.121 2.808 1 0.094 1.225 
Biomarker 
Panel (1 or 2) 
0.255 0.265 0.926 1 0.336 1.291 
BMI 0.045 0.022 4.369 1 0.037 1.046 
Age 0.020 0.012 2.582 1 0.108 1.020 
eGFR 0.003 0.008 0.165 1 0.684 1.003 
Gender 0.432 0.279 2.393 1 0.122 1.54 
Stroke / TIA -0.524 0.449 1.363 1 0.243 0.592 
Hypertension -0.619 0.267 5.382 1 0.02 0.539 
Heart Failure  -0.885 0.474 3.492 1 0.062 0.413 
Coronary 
artery disease 
-1.460 0.302 23.35 1 <0.001 0.232 
Diabetes -1.438 0.308 21.82 1 <0.001 0.237 
QT duration  0.007 0.003 6.853 1 0.009 1.007 
Constant -6.833 1.891 13.05 1 <0.001 0.001 
  
Discussion 
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The results of this combined analysis demonstrate that BNP independently predicts 
AF whereas FGF-23 does not. The ability of BNP to independently predict AF has 
already been established in previous studies and the results of this analysis are 
consistent with this. Elevated BNP levels predicting AF likely represent the 
haemodynamic loops of AF initiation/ maintenance. QT interval predicting AF 
independently is likely to be a reflection of the electrical/trigger loops.  
FGF-23 was not found to be an independent predictor of AF in this analysis. The 
reasons underlying this are unclear. From my earlier thesis chapters outlining 
biomarkers linked to AF, it was apparent that the role of FGF-23 in AF is not entirely 
clear; some studies found a link between high FGF-23 levels and AF whereas others 
not finding such a link. In this particular combined cohort, it is possible that other 
mechanisms other than fibrosis (FGF-23 being a surrogate marker), such as 
haemodynamic loops (represented by BNP) and electrical/trigger loops (represented 
by QT interval) play a greater role in AF genesis/maintenance and therefore the 
ability of FGF-23 to predict AF is limited.  
This logistical regression model design which includes biomarker panel as a covariate 
has been advised by Olink Proseek after email contact. Nonetheless, Olink Proseek 
itself confirmed that there was no standardised way of combining biomarker data 
extracted from 2 different biomarker panels and this was a method that may work. 
Given the rarity of such a situation, it must be highlighted that the statistical method 
which I have used as advised by Olink Proseek remains unvalidated in large cohorts 
so the results must be interpreted in this context. The lack of standardised statistical 
method to combine such data may also contribute to FGF-23 losing its ability to predict 
AF.  
Conclusion 
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Although I have attempted to combine data from both biomarker panels using a 
statistical technique recommended by the Olink Proseek, it is recognised that this 
technique is unvalidated and remains untested in large cohorts. BNP remains an 
independent predictor of AF along with QT and BMI. FGF-23 loses its ability to predict 
AF. Although the harmonisation of data is an appealing prospect and has been 
attempted in this Addendum, I do not feel that this is an adequately validated method 
to draw reasonable conclusions. I would therefore prefer to draw my main 
conclusions from the main discussion section from Chapter 7 where both panels were 
analysed separately.  
In the future, if further standardised statistical techniques are developed by Olink 
Proseek, it would be interesting to combine our data again to confirm our findings.  
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Chapter 7.  
Conclusion 
Summary of findings 
The burden of undiagnosed AF and its associated complications are being 
increasingly recognised. Although many patients with AF have clinical risk factors to 
develop AF, there is a large proportion of patients with AF who have no recognised 
risk factors.  
Therefore, biomarkers (blood based and ECG) are becoming increasingly used to 
abnormal pathophysiological mechanisms which can identify patients with AF and 
no recognised risk factors and also patients who are at risk of future AF.  
A novel proteomics chip technique was used to identify new and existing biomarkers 
associated with AF. Our study found that BNP was associated with an increased risk 
of AF and this is consistent with the current literature and therefore gives more 
confidence in this new technique.  
Our study also identified FGF-23 as a novel biomarker for AF. These two biomarkers 
independently predicted AF in a model consisting of recognised clinical risk factors.  
Simple and complex ECG markers were used to identify any potential predictors of 
AF. Prolonged QT interval was found to be the strongest independent predictor of AF 
and that complex ECG markers did not add significant additional predictive value. 
 A prolonged QT interval was associated with an increased risk of AF independently 
of recognised clinical risk factors.  
There are no large studies which have combined clinical parameters, blood based 
biomarkers and ECG markers to derive a combined model to predict AF in an “all 
comer” population presenting to hospital.  
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In the last results chapter, a combined model comprising of clinical risk factors, 
relevant ECG and blood based biomarkers using data from two biomarker panels 
(Cardiovascular Panel 1 and 2) was derived. This analysis demonstrated that when 
the combined model was applied to the Cardiovascular Panel 1 cohort, FGF-23, 
prolonged QT interval and male gender independently predicted AF. When the 
model was applied to Cardiovascular Panel 2, BNP and prolonged QT interval were 
independent predictors of AF.  
When comparing the various models a model consisting of blood based biomarkers 
only had a poor ability to predict AF. Models which included clinical variables only 
and ECG variables only both had a fair ability to predict AF.  
The real strength of the modelling becomes apparent when blood based biomarkers 
are combined with clinical parameters and ECG parameters. Such a combined model 
has a good ability to predict to predict AF and outperforms all the separate models 
and also contemporary models currently described in the literature.  
Overall, this combined model confirms and supports our current understanding of 
the pathophysiological mechanisms underlying AF generation and maintenance 
which includes four different positive feedback loops.  
The various clinical parameters may be surrogate markers for the haemodynamic 
and structural loops. The blood based biomarker BNP may also reflect the 
haemodynamic loop with FGF-23 reflecting the profibrotic pathway. Prolonged QT 
interval may be a surrogate marker for electrical and trigger loops.  
Blood based biomarkers have higher independent ability to predict AF in populations 
where clinical risk factors are not increasingly prevalent. In cohorts with a high 
proportion of heart failure patients for example, BNP has a dampened predictive 
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strength compared to populations where there is a lower proportion of heart failure 
patients.  
It is therefore important that the combined model comprises of clinical parameters, 
the relevant blood based and ECG biomarkers to cover the various mechanisms that 
could potentially contribute to AF generation.  
Different patients may have different pathophysiological mechanisms causing AF and 
our model consists of markers which act as surrogates for the distinct mechanisms 
that have been recognised in AF generation and maintenance. 
This model can potentially be used in routine clinical practice in the future as it is a 
simple model using basic clinical variables, ECG variables and a simple blood test. It 
could potentially be used to identify patients who are at risk of developing AF in the 
future and also patients who have undiagnosed AF who would therefore benefit from 
further rhythm monitoring for early AF diagnosis.  
It is anticipated that earlier diagnosis of AF will lead to instigation of the appropriate 
treatments such as thromboprophylaxis in specific patients with a subsequent 
reduction in AF related complications such as strokes.  
Limitations of the study 
This study has some limitations. Firstly, our study was a cross sectional study 
including patients with prevalent and not incident AF. The current BBC-AF cohort 
will be followed up for two years with opportunities to study outcomes data at that 
point. The model derived in this study can therefore be used for prospective validation 
at that point. 
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The BBC-AF cohort of AF patients included only prevalent AF, it is therefore not 
known whether patients who are at risk of AF but who are currently “AF – free” will 
display the same differences in blood based biomarkers and ECG parameters. 
 Secondly, the current biomarker panels used in this study measure relative rather 
than absolute protein concentrations. Depending on where our model is used such as 
the hospital laboratory, it would be perhaps more important if the relative protein 
concentrations could be converted to absolute protein concentrations.  This step is still 
under development and results are awaited.  
Thirdly, as the records were obtained from the medical notes, the precision of the 
study baseline characteristics rely on the accuracy of the medical records and 
diagnoses already derived by other healthcare professionals who have cared for the 
patients. The records were crosschecked as much as possible with GP records to 
ensure that patient clinical variables were correctly entered but it is possible that there 
may be small inaccuracies in some patients.  
Fourthly, with regards to AF diagnosis, the study design tried to exclude silent AF as 
much as possible by arranging for all the sinus rhythm patients to undergo 7-day 
event recorders to identify any AF.  Given the limitations of resources in a clinical 
environment, this is a reasonable method to exclude AF in such patient groups but it 
is possible that some patients may have paroxysms of AF outside of this 7-day 
window which is therefore not identified. In order to address this issue, an 
implantable reveal device may be the answer but this is a more invasive procedure 
with a much larger associated cost. 
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Implications of using CHA2DS2-VASc to recruit patients in the sinus rhythm group 
Although CHA2DS2-VASc scoring has been designed to predict the risk of stroke in 
patients with atrial fibrillation, there has recently been increasing interest in the use of 
CHA2DS2-VASc scoring to predict risk of mortality even in patients without AF.  
Yoshihisa et al (153) investigated the use of CHA2DS2-VASc score in predicting 
mortality in patients with heart failure. 1011 patients admitted with heart failure 
were followed for a median of 801 days. The CHA2DS2-VASc score, especially if the 
score was 7-9, was an independent predictor of all cause mortality in heart failure 
patients irrespective of whether they had AF or not.  Yung-Lung Chen et al (154) 
followed up 1311 patients with systolic heart failure (with or without AF). At 1 year 
follow up period, the CHA2DS2-VASc score independently predicted all mortality in 
patients with systolic heart failure in patients with and without AF.  
Mazzone et al (155)  investigated the ability of the CHA2DS2-VASc score in 
predicting cardiovascular events and death in patients with arterial hypertension 
and sinus rhythm. Although the study was primarily designed to investigate sinus 
rhythm patients, they also had a relatively small number of patients with non-
valvular AF as a comparator. Nearly 13000 patients (11,159 sinus rhythm, 1440 AF 
patients) were followed up for around 3 years. Higher CHA2DS2-VASc scores 
predicted higher rates of thromboembolic events in sinus rhythm patients, with a 
similar expected trend noted in AF patients. CHA2DS2-VASc score was found to be a 
moderate/good predictor of adverse events (thromboembolic events, cardiovascular 
hospitalisation and all-cause death) in both AF and sinus rhythm patients. There was 
no significant difference in the ability of CHA2DS2-VASc to predict adverse events 
between sinus rhythm and AF patients.  
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In our study, even though patients were selected in a consecutive manner, there 
were differences in demographics which were apparent between our AF and sinus 
rhythm patients. For example, patients in our sinus rhythm group had a significantly 
higher proportion of coronary artery disease and diabetes compared to the AF group 
and overall may actually have a higher underlying CHA2DS2-VASc score.  The 
reasons for this are likely to be related to two main factors. Firstly, the inclusion 
criteria for sinus rhythm patients to be enrolled into BBC-AF included that patients 
should have essentially a CHA2DS2-VASc score of 2 or more. This CHA2DS2-VASc 
requirement was not an inclusion criteria for AF patients. Secondly, although 
enrollement was consecutive and unselected on a daily basis, the exact location in 
hospital where patients were recruited from could have had an impact on the 
CHA2DS2-VASc core. We tried to recruit a significant proportion of patients from the 
Medical Assessment Unit but sometimes patients in this ward were unwilling to 
take part in studies as they were acutely being admitted and treated for their 
medical problems. Patients from my base ward (Cardiology wards) were generally 
keener to be recruited into the study. Most of these patients will have coronary 
artery disease and as diabetes is a significant risk factor for coronary artery disease, 
it is not too surprising that there is a high proportion of diabetes found in these 
patients.  
The current study is cross-sectional and describes baseline differences between AF 
and sinus rhythm groups in terms of clinical parameters, ECG and blood-based 
biomarkers. There is a planned 2 year follow up project for all of the patients 
recruited into the BBC-AF registry. Although AF is an adverse prognostic marker in 
itself, it will be attractive to investigate the effect of the likely higher CHA2DS2-VASc 
score in our sinus rhythm patients in terms of mortality, thromboembolic 
complications and so on at the 2 year follow up. Based on the literature published 
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above, it is possible that the mortality difference between AF and sinus rhythm 
patients may actually be non-significant or even higher in the sinus rhythm group.  
 
 Suggestions for future studies. 
This study of an unselected population presenting to a hospital investigated prevalent 
AF but no prospective outcome data. The results of this study invite larger, 
prospective studies to validate the current combined model in similar populations.  
A large proportion of the patients in this study had multiple comorbidities therefore 
making it more difficult to investigate the exact role of blood based biomarkers 
especially FGF-23 in the pathophysiology of AF when combined with clinical risk 
factors.  
In order to investigate the role of FGF-23 more closely, it would be ideal to have a 
population of patients with AF with no recognised clinical risk factors. In this study, 
the number of patients with no recognised clinical risk factors was too small to derive 
any significant results but a larger study of such patients would be useful in validating 
and expanding our understanding of the role of these biomarkers in AF 
pathophysiology.  
Conclusion 
In this study, a simple model has been derived for  AF prediction consisting of clinical 
variables, 1 ECG variable and 2 blood based biomarkers.  
FGF-23 has been identified as a novel biomarker for the prediction of AF. This model 
will be useful in identifying patients at risk of AF and also patients with undiagnosed 
AF who may need more intensive investigations.  
There is a need for further validation of this novel model in large, prospective datasets.  
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Addendum  
List of 40 overlapping biomarkers from Cardiovascular Panel 1 and 2 used for 
biomarker analysis in this thesis.  
Biomarker Abbreviation 
Adrenomedullin ADM 
Agouti-related protein AGRP 
Angiopoietin-1 receptor TIE2 
Cathepsin L1 CTSL1 
C-C motif chemokine 3 CCL3 
CD40 ligand CD40L 
C-X-C motif chemokine 1 CXCL1 
Dickkopf-related protein 1 Dkk-1 
Fibroblast growth factor 23 FGF-23 
Follistatin FS 
Growth hormone GH 
Heat shock 27 kDa protein HSP 27 
Heparin-binding EGF-like growth factor HB-EGF 
Interleukin-1 receptor antagonist protein IL-1ra 
Interleukin-16 IL-16 
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Biomarker Abbreviation 
Interleukin-18 IL-18 
Interleukin-27 IL-27 
Interleukin-6 IL-6 
Lectin-like oxidized LDL receptor LOX-1 
Leptin LEP 
Matrix metalloproteinase-12 MMP-12 
Matrix metalloproteinase-7 MMP-7 
Melusin ITGB1BP2 
Natriuretic peptides B BNP 
NF-kappa-B essential modulator NEMO 
Pappalysin-1 PAPPA 
Pentraxin-related protein PTX3 PTX3 
Placenta growth factor PIGF 
Platelet-derived growth factor subunit B 
PDGF subunit 
B 
Proteinase-activated receptor 1 PAR-1 
Proto-oncogene tyrosine-protein kinase Src SRC 
P-selectin glycoprotein ligand 1 PSGL-1 
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Biomarker Abbreviation 
Receptor for advanced glycosylation end products RAGE 
Renin REN 
Stem cell factor SCF 
Thrombomodulin TM 
TIM.1 TIM-1 
Tissue factor TF 
TNF-related apoptosis-induced ligand receptor 2 TRAIL-R2 
Vascular endothelial growth factor D VEGF-D 
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